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Abstract 
Skeletal muscle and its progenitor cells are formed during the development. In adulthood the 
progenitor cells remain inactive until a differentiation signal is sensed, such as an exercise or 
tissue damages. Under certain conditions like aging, chemotherapy and genetic disorder, the 
capacity of skeletal muscle regeneration declines and progenitors can’t differentiate properly, 
resulting in immobilizing problems. Embryonic stem (ES) cells have been highlighted as a great 
source which can provide amplifiable skeletal muscle progenitors. ES cells have the capacity of 
self-renewal and the potential of differentiation into every cell type in the human body, including 
skeletal muscle. Although amplifiable skeletal muscle can be differentiated from ES cells by 
ectopic over-expression of key transcription factors, genetic integration of cDNA into host is a 
prerequisite. Therefore, efforts have increasingly focused on the identification of small 
molecules which can induce skeletal muscle differentiation from ES cells in the field. Using 
small molecules for cellular differentiation provides invaluable advantages compared to other 
methods such as genetic modifications. Modulation of signaling by small molecules is rather 
straight forward and the effect can be controlled with a fine-tuning manner by applying various 
concentration and time points. In spite of the prominent advantages, there has been no single 
molecule known to drive ES cells at high efficiency to skeletal muscle thus far.  
My thesis work was focused on the identification of small molecules which can drive 
differentiation of mouse embryonic stem cells toward skeletal muscle. I also investigated the 
biological process during embryonic skeletal muscle differentiation that manipulates the 
development process taking place in vivo. Embryonic stem cells have been a popular tool for 
studying development processes as well as a great source for cell therapy via manipulations of 
physiological events. In this study a small molecule was identified from a mouse embryoid body 
(EB) screening and used as a tool compound for skeletal muscle differentiation. The small 
molecule was named as SMI (Skeletal Muscle Inducer). Its chemistry is N-[4-(trifluoromethyl)-
6-methoxymethyl-2-pyrimidinyl]-N-(2-methyl-6-nitrophenyl)-urea. In the screening Pax3 
mRNA induction was one of the major readouts since Pax3 has been known as a key 
transcription factor for early skeletal muscle development. SMI1 showed a high efficiency for 
skeletal muscle differentiation without any extra effort such as fluorescent cell sorting step. Even 
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though the effect of the compound driving mouse ES cells from 129 mice to skeletal muscle was 
very clear, it did not have the same effect in ES cells of other mouse strains, BalbC and Bl6. By 
discovering the mechanism of action of this small molecule, I expect that it could be applied and 
transferred to other cell lines as well as human pluripotent stem cells. These insights can pave 
way to determining the complexity of embryonic skeletal muscle differentiation.  
Comprehensive gene expression level analysis with SMI incubation resulted in the discovery of 
three pathways which are involved and play critical roles in skeletal muscle differentiation by the 
molecule. Wnt pathway and Nodal pathway were identified from EB day 4, and Shh signaling 
was found at EB day 4+4. All the three pathways are closely related to the development process 
of the mouse embryo. The action of SMI1 was reproduced independently using other small 
molecules which are known to modulate the Wnt, Nodal and Shh pathways in all mouse ES cells 
from different strains tested. Taken together, these results demonstrate that the differentiation of 
mouse embryonic stem cells into skeletal muscle by SMI1 occurs through Wnt, Nodal and Shh 
pathways’ modulation. Therefore, SMI1 can be used as a tool to study the skeletal muscle 
biology and to establish a cellular skeletal muscle disease model for therapeutic research.  
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Chapter1: Introduction 
1.1 Skeletal muscle disease 
1.1.1 Skeletal muscle 
The human body consists of around 600 individual skeletal muscles which covers about 40% of 
an adult’s body mass (Reviewed in Jung and Williams, 2012). Skeletal muscle is composed of 
thousands of muscle fibers that are multinucleated and are formed during development by the 
fusion of mononucleated myoblasts. They are surrounded by a specialized plasma membrane, the 
sarcolemma, which transduces signals from motor neurons to muscle fibers. Skeletal muscle can 
adapt muscle fiber size, functional capacity and metabolism in response to physiological stimuli. 
Severe muscle damage activates satellite cells, which are resident population of stem cells to 
proliferate and differentiate in order to rebuild the new muscle. Satellite cells were identified on 
the basis of their distinct anatomical position between the sarcolemma and the basal lamina of 
muscle fibers (Mauro, 1961). The basal lamina is composed of layers of extracellular matrix 
known as the basement membrane of muscle fibers (Sanes, 2003). 
The regenerative potential of adult muscle depends on the endogenous source of muscle 
progenitor cells, satellite cells (Goldring et al., 2002). Satellite cells stay mitotically and 
metabolically quiescent through most of life. Quiescent satellite cells are triggered to proliferate 
by growth factors and cytokines which are released after damage to skeletal muscle. They 
include insulin-like growth factor, epidermal growth factor and platelet-derived growth factor 
(Ciemerych et al., 2011).  
Molecular mechanism of the skeletal muscle mass regulation in adulthood can be explained as 
the balance between relative rate of protein synthesis and degradation (Reviewed in Schiaffino et 
al., 2013). Growth of muscle occurs through increases in myofiber size by protein synthesis 
exceeding protein degradation, which is a process of hypertrophy. Conversely, loss of muscle 
mass is mediated by loss of proteins, organelles and cytoplasm, which is a process of atrophy. 
FoxO3, which is negatively regulated by Akt, controls well known muscle-specific atrophy-
related ubiquitin ligases such as Atrogin1 (MAFbx). Atrogin1 is an E3 ubiquitin ligase, regulated 
by FoxO (Forkhead box O) transcription factors, which catalyzes the rate-limit step in the 
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ubiquitination process (Sandri et al., 2004). Recent studies suggest that other potential key 
cellular processes may also be involved in causing skeletal muscle related diseases. For example, 
the TGFbeta superfamily may cause skeletal muscle waste by coordinating the balance between 
protein degradation and synthesis, according to the physiological state of the muscle fibers 
(Reviewed in Sartori et al., 2014). It is well known that Myostatin, a member of TGFbeta family, 
is a negative regulator of muscle growth (McPherron and Lee, 1997). Recent findings suggest 
that Myostatin’s effect on muscle mass may also be involved with the activation of Atrogin1 and 
inhibition of IGF1/Akt/mTOR pathway (Trendelenburg et al., 2009). The exact mechanism of 
the TGFbeta family on protein degradation still remains unclear. Further investigations are 
needed to reveal the mechanisms and pathways downstream of Smad2/3 by the TGFbeta family 
during protein synthesis and degradation.  
1.1.2 Skeletal muscle diseases 
Skeletal muscle wasting and diseases are caused by the loss or absence of ability of skeletal 
muscle to control muscle mass. Muscle atrophy can also occur because of muscle inactivity from 
immobilization, casting and age-related loss of skeletal muscle. The skeletal muscle diseases 
caused by genetic disorder or ageing are described in detail below. 
1.1.2.1 Genetic diseases of skeletal muscle 
Genetic disorder can cause muscle degenerative diseases too. For example, mutations in the 
dystrophin gene results in Duchenne muscular dystrophy (DMD), the most common X-linked 
genetic disorder in humans (Burghes et al., 1987). Point mutations in dystrophin are responsible 
for 40% of DMD cases and the remaining 60% are caused by large deletions or duplications in 
this gene (Chaturvedi et al., 2001). Most boys with DMD show symptoms within the first years 
of life. The symptom is progressive muscle weakening resulting in walking delay and repeated 
falls. Dystrophin is a structural protein which is a component of the DGC (dystrophin 
glycoprotein complex) (Ervasti and Campbell, 1991). Dystrophin links the muscle fiber 
cytoskeleton to the extracellular matrix and stabilizes the sarcolemma (Straub et al., 1992). 
Absence of functional dystrophin protein destabilizes DGC and increases the susceptibility of 
dystrophic muscle fibers to contraction induced injury (Campbell and Kahl, 1989). 
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Myotonic dystrophy type 1 is also a well-studied genetic skeletal muscle disease. It is known as 
dystrophia myotonica type 1 (DM1), an autosomal dominant disease caused by a trinucleotide 
repeat, cytosine-thymine-guanine (CTG), expansion in the 3’ UTR of DMPK (Dystrophia 
Myotonica Protein Kinase) on chromosome 19 (Brook et al., 1992). Normal individual have less 
than 30 repeats, and expansions more than this range can initiate DM symptoms. CTG repeat 
expansions of the DMPK 3’UTR are transcribed into mRNA and form intranuclear foci, 
resulting in nuclear retention of DMPK mRNA. Age of onset and disease severity appear to 
correlate with repeat expansion length. The symptom of DM is myotonia or the inability to relax 
skeletal muscles after contraction. Additional DM symptoms include skeletal muscle wasting and 
weakening, smooth and cardiac muscle malfunction. 
1.1.2.2 Progressive loss of skeletal muscle by ageing 
In a society where the increasing aged population is becoming more prevalent, age-related 
decline in muscle mass and strength are present and growing health concerns. Progressive 
muscle wasting, known as sarcopenia, is a decrease in skeletal muscle mass associated with 
aging which compromises the ability to live independently at advanced age. The underlying 
molecular mechanisms which contribute to the progression of sarcopenia are not clearly known 
yet (Reviewed in Lang et al., 2010). Current potential causes of sarcopenia include an increase in 
chronic inflammation, metabolic processes that lead to increased insulin resistance, activated 
catabolic pathways, accumulation of genotoxic DNA damage and insufficiency in satellite cells 
that impair the normal muscle regenerative response.  
1.1.3 Therapeutic possibilities for skeletal muscle diseases 
Current therapeutic options for skeletal muscle disease are very limited and focus on managing 
symptoms and suppressing the inflammatory response (Muir and Chamberlain, 2009). Some 
investigators have focused on development of direct gene therapy in affected muscle fibers by 
exogenous delivery of a normal copy of the mutated gene for example dystrophy genes using 
viral vectors (Partridge, 2011). However, viral vectors are susceptible to antiviral host immune 
responses which can prevent repeated gene-delivery attempts.  
Cell therapy is another attractive option to treat the skeletal muscle disease through the delivery 
of cells which can regenerate new skeletal muscle tissues (Darabi et al., 2012). Cell therapy 
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involving transplantation of multi-potent hematopoietic stem cells derived from bone marrow 
has already been demonstrated as a successful option (Thomas et al., 1957), however it did not 
give rise to skeletal muscle diseases. Early clinical trials tested the efficacy of transplanted 
myoblasts from explants of donor muscle and injected directly into the muscle. Unfortunately the 
trials were not successful (Miller et al., 1997). Perhaps it was because of significant cell loss 
after transplantation caused by the death of injected cells.  
Due to the challenges in studies using satellite cells which cannot be amplified in vitro easily, 
researchers in this area have tried to establish skeletal muscle differentiation from pluripotent 
stem cells (Chang et al., 2009; Sakurai et al., 2008). By taking advantage of pluripotent stem cell 
differentiation potential, amplifiable skeletal muscle stem cells might be obtainable. Current 
methods for skeletal muscle differentiation from pluripotent stem cells involve either treating 
cells biochemically or through genetic modification resulting in over-expression of master genes 
(Darabi et al., 2008; Kennedy et al., 2009). Progress in the ability to isolate and expand satellite 
state cells from pluripotent cells will also be an essential step for cell therapy approaches. 
Considering the embryonic stem cells’ potentially unlimited capacity for self-renewal and ability 
to differentiate into the muscle, embryonic stem cells may be a great source for cell therapy  and  
useful in creating cellular models for biomedical research. 
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1.2 Skeletal muscle development  
1.2.1 Early Skeletal Muscle Development 
1.2.1.1. Primitive streak formation at embryonic day 6.5 
Vertebrate skeletal muscle differentiation is controlled tightly by morphogens secreted from 
neighbor tissues in a spatiotemporal manner (Reviewed in Gurdon et al., 1998). Morphogens 
control the genetic networks and the pattern of tissues in developing embryos. During mouse 
development skeletal muscle is differentiated from mesoderm which arises around embryonic 
day 6.5 with the primitive streak formation (Reviewed in Tam and Behringer, 1997). 
Gastrulation after primitive streak formation is a pivotal step in setting the vertebrate body plan. 
In gastrulation stage, primary germ layers appear that are ectoderm, mesoderm and definitive 
endoderm. Ectoderm develops further to neurons mainly and endoderm makes lung, liver and 
pancreas for instance. Nodal is a key effector together with BMP4 and Wnt family for the initial 
mesoderm formation (Conlon et al., 1994; Hogan, 1996; Yamaguchi, 2001).  
  
Figure 1.1: E6.5 Primitive-streak formation Primitive streak is a structure that 
forms in the posterior region of the embryo and is the first visible sign of gastrulation 
at E6.5 (Adapted from Tam and Loebel, 2007).  
Anatomically mesoderm is subdivided to four main tissues which are paraxial, intermediate, 
chorda and lateral plate mesoderm depending on the position from the midline (Reviewed in 
Tam and Loebel, 2007). In the primitive streak of the late gastrula, the paraxial mesoderm, also 
called somatic dorsal mesoderm, comes from the anterior segment of the streak. It is forming the 
somite which is a block of mesodermal cells on both sides of the neural tube. The lateral 
mesoderm comes from the mid-segment of the streak and forms the circulatory systems 
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including heart, blood vessels and blood cells as well as the lining of the body cavities and all the 
mesodermal components of the limbs except the muscles. Intermediate mesoderm forms the 
urogenital system, kidney and gonads. Chordamesoderm forms the notochord which is a 
transient organ. The major function of notochord is the induction of the formation of the neural 
tube.  
1.2.1.2. Somitogenesis at embryonic day 9 
Paraxial mesoderm experiences presomitic mesoderm stage which is still unsegmented, moving 
along from the posterior tail bud region to the anterior. As the cells in the presomitic mesoderm 
(PSM) differentiate further, they move to the anterior region. Receiving the differentiation signal 
of morphogen gradients, condensed paraxial mesoderm makes somites which will be further 
differentiated into connective tissues of the back such as bone, muscle, cartilage and dermis. It is 
known that the formation of somites is mediated by Wnt pathway and the gradient of FGF and 
retinoic acid (Aulehla and Pourquie, 2006). Wnt1 and Wnt3 are secreted from the dorsal neural 
tube and are positively involve in somite patterning. Sonic Hedgehog (Shh) which is released 
from the notochord mediates muscle progenitors’ specification in somite. Unlike Wnt and Shh, 
bone morphogenetic protein (BMP) works negatively in skeletal muscle development, delaying 
induction of Myf5 and MyoD and keeping the muscle progenitors in an undifferentiated state 
(Pourquie et al., 1996). Wnt and Shh antagonize BMP signals in the dermomyotome through 
increased levels of Noggin, which inhibits Bmp4 signal (Marcelle et al., 1997). Pathways which 
are involved in this process will be mentioned in detail below.  
At the genetic level, it was reported that the differentiation and movement of PSM progenitor 
cells are regulated by the transcription factor Mesogenin1 (Fior et al., 2012). Mesogenin1 
controls the genesis of the paraxial mesoderm and maintains the differentiation to its derivatives. 
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Figure 1.2: Pax genes and myogenic stem cell populations 
The timing of muscle development in the embryo and postnatal periods in mouse is indicated. 
Skeletal muscle is marked in blue in the embryo. Embryonic and foetal muscle progenitors 
cells are in red and the period of satellite cells is marked in yellow color. The function of 
Pax3 and Pax7 genes are indicated (Adapted from Relaix and Zammit, 2012). 
 
1.2.1.3. Embryonic skeletal myogenesis in dermomyotome 
All the skeletal muscles, except some head muscles, are differentiated from dermomyotome. 
Cells in dermomyotome express the paired box transcription factors Pax3 and Pax7 (Goulding et 
al., 1991; Jostes et al., 1990). And they are also marked by low level of Myf5, a basic helix-loop-
helix transcription factor (Kiefer and Hauschka, 2001). In muscle progenitors, MyoD is 
downstream of Pax3 and Pax7 in the genetic hierarchy of myogenic regulators (Bismuth and 
Relaix, 2010). The dermomyotome matures into the myotome, which consists of muscle cells 
expressing MyoD and Myf5 considered to be markers of terminal specification of the muscle 
lineage (Pownall et al., 2002).  
The myogenic regulatory factors (MRFs) are MyoD, Myf5, Mrf4 (also known as Myf6) and 
Myogenin. MRFs are basic helix-loop-helix structured transcription factors which can convert 
fibroblast to myoblast (Braun et al., 1990; Davis et al., 1987; Rhodes and Konieczny, 1989). 
They are highly conserved and expressed in the skeletal muscle lineage. The basic domain of the 
basic helix-loop-helix transcription factor mediates DNA binding to the CACCTG sequence 
while the helix-loop-helix motif is required for heterodimeriation with E-proteins that mediate 
the recognition of genomic E-boxes (CANNTG sequence) in the promoters of many muscle-
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specific genes(Massari and Murre, 2000). In the mouse embryo myotome, Myogenin is 
downstream of Myf5 and Mrf4. The promoter regions of Myogenin contain two E-Boxes directly 
bound by Myf5, MyoD and Mrf4 (Bismuth and Relaix, 2010). 
1.2.2. Mouse model studies in development 
Expression of Pax3 is found in various tissues during development such as the dorsal neural tube, 
neural crest cells and muscle progenitors (Goulding et al., 1991). The absence of Pax3 causes 
impaired muscle development as well as neural crest cell loss and dorsal neural tube closure 
defects (Bajard et al., 2006). In contrast Pax7 is not mandatory for muscle development because 
the phenotype of Pax7 absence is pronounced at the post-natal stage (Seale et al., 2000). Pax7-
deficient mice show a loss of satellite cells after birth suggesting that Pax3 can’t compensate the 
loss of Pax7 in satellite cells’ post-natal survival. Muscle precursor cells can’t enter the 
myogenic program in Pax3/Pax7-double mutant mice (Relaix et al., 2005). 
Inactivation of MyoD in mice leads to upregulation of Myf5 which compensates the function of 
MyoD and results in apparently normal muscle development (Rudnicki et al., 1992). Also normal 
skeletal muscle phenotype was reported in Myf5 knockout mice (Braun et al., 1992). Myf5 is 
dispensable for the development of skeletal muscle, because other members of the myogenic 
regulatory factors such as MyoD, Myogenin and Mrf4 substitute for its activity. In Myf5 and 
MyoD double-null mice, complete lack of skeletal muscle and Myogenin expression appeared 
(Rudnicki et al., 1993). Myogenin knockout mice showed reduced levels of Myosin heavy chain 
and Mrf4 expression but normal MyoD level (Hasty et al., 1993). Myogenin-mutant mice have 
no muscle defect showing normal development but malfunctioning skeletal muscle after birth. It 
suggests that Myogenin is critical for the progression of functional skeletal muscle. These results 
suggest a model in which MyoD and Myf5 act genetically upstream of Myogenin to specify 
muscle precursors for terminal differentiation (Bentzinger et al., 2012). 
1.2.3 Pathways involved in early skeletal muscle formation 
Here I introduce the biological background of pathways involved in early skeletal muscle 
development in detail. 
1.2.3.1 TGF (Transforming growth factor)-beta family 
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TGF-beta and its family, such as Nodal, Activin, Bone Morphogenetic Proteins (BMPs), 
Myostatins, have been studied extensively and their mechanism of action is very well known. 
The biological actions of TGF-beta signaling are dependent on the combination of ligands and 
receptors. They have profound effects on many events from cell propagation, differentiation, 
migration to death (Reviewed in Massague, 1998). Nodal signals are essential for the induction 
and patterning of mesoderm and endoderm (Conlon et al., 1994). BMPs were originally 
identified because of their role in early bone formation. Their functions in skeletal muscle 
development are to expand the pool of myogenic progenitor cells before further differentiation is 
initiated (Pourquie et al., 1996).  
Ligand binding to a TGF-beta type II receptor completes a receptor complex together with a 
TGF-beta type I receptor. The constitutively active type II receptor kinase phosphorylates and 
activates the type I receptor. Activins, TGF-betas and Nodal bind to type I receptors, Activin 
Receptor-like Kinase ALK4, ALK5 (TGF-beta receptor I) and ALK7, respectively. Activation of 
the type I receptor in turn phosphorylates a Smad protein which is one of receptor-regulated 
Smad (R-Smad) proteins. Phosphorylated R-Smad proteins make a complex with Co-Smad, 
Smad4, and move to the nucleus. In the nucleus, the Smad complex plays a role as a transcription 
factor activating the transcription of target genes. For example, p15Ink4b and p21Cip21 are cyclin-
dependent kinase inhibitors responding to TGF-beta mediated cell cycle arrest. 
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Figure 1.3: Type I and II TGF-beta receptor families. 
In type I TGF-beta receptors the protein kinase domain is preceded by the GS domain 
which is a unique feature of type I receptors containing SGSGSG sequence. Ligand-
induced phosphorylation of the serines and threonines in the TTSGSGSG sequence is 
required for activation of signaling. Arrows indicate the phosphorylation sites. 
(Adapted from Massague, 1998) 
 
The evolutionary conserved Smad proteins are direct mediators of TGF-beta and its family 
members’ signaling. There are eight Smad proteins identified, Smad1 to Smad8/9 in the human 
and mouse genomes (Reviewed in Massague et al., 2005). R (regulatory)-Smads are Smad1, 
Smad2, Smad3, Smad5 and Smad8. Smad1, 5, and 8 act as substrates for the BMP receptors. 
Smad2 and 3 are substrates for the TGF-bata, Activin and Nodal receptors. Smad4 which is a 
Co-Smad acts as a common effector for all R-Smads. Smad6 inhibits BMP signaling and Smad7 
inhibits TGF-beta and BMP signaling. 
1.2.3.2 Wnt Pathway 
19 Wnt genes have been identified in the murine and human genome so far. (Wnt homepage 
http://web.stanford.edu/group/nusselab/cgi-bin/wnt/) The Wnt pathway consists of two different 
main streams, the canonical (beta-catenin dependent, prototype canonical Wnt3a) pathway and 
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the non-canonical (independent of beta-catenin, prototype Wnt5a) pathway (Reviewed in 
Grumolato et al., 2010; Seifert and Mlodzik, 2007). 
• Canonical Wnt Pathway 
 
Figure 1.4: Activation Scheme of Canonical Wnt Pathway 
In the presence of Wnt ligand, the receptor complex forms between Lrp5/6 and Frz 
leading to beta-catenin stabilization and localization to nucleus. Beta-catenin in the 
nucleus acts as a coactivator for TCF activating Wnt-responsive genes (Adapted from 
MacDonald et al., 2009). 
The canonical Wnt Pathway is involved in various biological processes in embryonic 
development, cell fate determination and adult tissue homeostasis. One key effector of Wnt 
Pathway is β-catenin. β-catenin is phosphorylated by the complex of Glycogen synthase kinase 3 
(GSK3), Axin and Adenomatous polyposis coli (APC) constitutively and degraded through the 
ubiquitin proteasome pathway (Reviewed in MacDonald et al., 2009). Binding of Wnt to its 
receptor, LRP5/6 leads to disconnection of β-catenin from its degradation complex and stabilizes 
β-catenin which translocates to nucleus. β-catenin in nucleus binds to Wnt response gene and 
induces transcriptional activation. Irregular activation of Wnt pathway due to mutations in APC 
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is linked not only to colorectal cancer but also to some other cancers such as those of liver 
(Reviewed in Aoki and Taketo, 2007).  
During mouse embryo development, the Wnt pathway is related closely to neurogenesis and 
anterior-posterior patterning (Reviewed in Yamaguchi, 2001). Wnt3a mutant mice do not show a 
proper anterior-posterior body axis (Ikeya and Takada, 2001). It has been also reported that Wnt 
signal is indispensable for neuronal induction and skeletal muscle differentiation. Wnt3a mutant 
embryos lack somites, have a disrupted notochord and fail to form a tailbud (Takada et al., 1994). 
Mutant embryos also show brain dysmorphology. At the molecular level Wnt targets Brachyury, 
Mesogenin1, Tbx6 and Axin2 which are important to maintain cells in a posterior PSM fate 
(Aulehla and Pourquie, 2010). 
1.2.3.3 Sonic Hedgehog Pathway 
Hedgehog protein families are secreted glycoproteins that control the multiple developmental 
processes of many organs and cell groups in metazoans (Reviewed in Ingham et al., 2011). In 
mammals, there are 3 Hh ligands identified, Sonic (Shh), Indian (Ihh) and Desert (Dhh). Shh is 
involved in neural development in vertebrates and Ihh participates in bone growth and endoderm 
differentiation. Dhh is known to mediate spermatogenesis (Clark et al., 2000). In the normal 
central nervous system of mammals and birds, only Shh is reported to be expressed (Echelard et 
al., 1993). The Hh proteins bind to the cell surface receptor Patched1 (Ptch1) resulting in release 
of inhibition on G protein-coupled receptor like protein Smoothened (Smo). Smo translocates to 
the plasma membrane from intracellular vesicles. Active Smo regulates gene expression through 
nuclear translocation of the zinc-finger Gli transcription factors. 3 Gli proteins are identified and 
they mediate the responses to Hh signals. Gli2 is a transcription activator mediating the Hh 
pathway primarily. Gli1 whose expression is regulated by Gli2 and Gli3 also activates 
transcription of target genes such as Gli1, Ptch1, Ptch2 and Bcl2. In contrast, Gli3 is a 
transcription repressor. 
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Figure 1.5: Shh-triggered intracellular events resulting in Gli function. 
Upon Shh binding to the Ptch1-Smo receptor, a macromolecular complex produces 
Gli activators. The Macromolecular complex is associated with Su(fu) (Suppressor of 
fused), Fu (Fused), PKA, the Gli proteins and other possible components represented 
as X, Y, Z (Adopted from Ruiz i Altaba et al., 2002). 
During development, the neural tube and notochord secret Shh. Together with Wnt proteins, Shh 
also mediates the specification of muscle progenitors in the somite. A genetic study in mice 
where Shh was deleted showed significant reduction of Myf5 mRNA and similar level of MyoD 
protein compared to wild type mice (Chiang et al., 1996). However, in a laterstage of Shh mutant 
embryos, the appearance of skeletal muscle indicates that differentiation of myotomal derivatives 
does not require Shh function. Shh is essential for the maturation of skeletal muscle progenitors 
into Myf5 expressing committed cells (Borycki et al., 1999; Borycki et al., 1998). In chicken 
embryos, ectopic overexpression of Shh upregulates the level of Pax1, sclerotomal marker but 
inhibites the expression of Pax3 in the dermomytome (Johnson et al., 1994). 
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1.3 Embryonic stem (ES) cells  
1.3.1 What are ES cells 
ES cells are originated from the inner cell mass of a blastocyst. They can proliferate unlimitedly 
and can be maintained in vitro without any loss of differentiation potential (Ying et al., 2008). In 
1981, Evans and Kaufman succeeded to cultivate  pluripotent stem cell lines from mouse 
blastocysts, taking a feeder layer of mouse embryonic fibroblasts (Evans and Kaufman, 1981). 
Martin also established embryonic pluripotent cells in the same year using embryonic carcinoma 
cell-conditioned medium (Martin, 1981). Pluripotency of these cell lines was demonstrated in 
vivo by injecting ES cells back into blastocysts. The successful generation of chimeric mice 
demonstrate that ES cells keep the full developmental potency to contribute to all cell lineages 
including the germ line (Bradley et al., 1984). Later, Leukemia inhibitory factor (LIF) was 
identified as the trophic factor in the culture medium which suppresses differentiation of the ES 
cells, (Williams et al., 1988). LIF is a soluble glycoprotein of the interleukin-6 family of 
cytokines. It acts through a membrane-bound gp130 signaling complex to regulate a variety of 
cell functions (Burdon et al., 1999). The signal cascade of the receptor involves the JAK kinase 
mediated activation and STAT3 transcription factor recruitment. An external signal, LIF, keeps 
ES cells undifferentiated by regulating the pluripotent genes such as Oct4, Nanog and Sox2 
(Chen et al., 2008). Oct4 is a POU domain transcription factor which plays a critical role in 
maintaining ES cell pluripotency. Oct4 deficient mouse embryos fail to develop beyond the 
blastocyst stage because of the lack of pluripotent inner cell mass (Nichols et al., 1998). Nanog 
also maintain the undifferentiated state of pluripotent epiblast. Nanog was described as a 
regulator for cell fate decision of the pluripotent stem cells during embryonic development. It 
prevents the differentiation of ES cells to primitive endoderm (Chambers et al., 2003).  
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Figure Stem cell hierarchy. ICM stands for the inner cell mass. ESC 
represents embryonic stem cells. 
Zygote and Morula stage are defined as totipotent. At blastocyst stage only 
the cells of inner cell mass retain the capacity to differentiate to all three 
primary germ layers. In adult tissues, multipotent stem and progenitors exist 
in tissues and organs to replace lost or injured cells. (Adapted from Wobus 
and Boheler, 2005) 
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1.3.2 In vitro differentiation of ES cells 
During mouse development, three germ layers interact to form all tissues and organs of the 
embryo. The in vitro differentiation potential of mouse ES cells has been tested in comparison 
with these in vivo developmental processes. Differentiation of mouse ES cells can be initiated by 
making 3D aggregations of dissociated cells in the absence of LIF or feeder cells. This process is 
called embryoid body (EB) formation (Reviewed in Boheler et al., 2002). In EBs it was shown 
that ES cells can be differentiated into all three primary germ layers by showing the temporal 
expression of tissue specific marker genes and proteins (Leahy et al., 1999). By providing the 
proper differentiation environment, in principle ES cells can be pushed to almost all the somatic 
cells. 
Thanks to the feature and potency of ES cells to differentiate to somatic cells, we can take 
advantage of them for several purposes in the area of biomedical research. First, differentiated 
somatic cells from ES cells are helpful for disease model generation at cellular level for the 
development of therapeutics (Chen et al., 2009a). Also ES cells can be a useful tool to establish 
the cellular disease model in order to study the pathological background of disease, where animal 
model is not available due to embryonic lethality. For instance, since homozygous disruption of 
mouse SMN (survival motor neuron) is lethal, it was not possible to isolate tissue from adult 
animals. However by using spinal muscular atrophy motor neurons derived from homozygous 
mouse ES cells in vitro, it was possible to do a transcriptome profiling study (Maeda et al., 
2014). In this study, the gene expression levels in motor neurons derived from cell lines with or 
without SMN were compared. By this comparison it was discovered that pluripotency and cell 
proliferation transcripts were significantly increased in SMA motor neurons, while transcripts 
related to neuronal development and activity were reduced.  
In a similar way ES cells differentiation system can be applied for uncovering unknown genes’ 
function via genetic manipulation. In the case of functional study on lysine methyltransferase 
(KMT1E previously known as ESET or Setdb1) which mediates histone H3-K9 methylation, no 
ES cell lines could be obtained from the inner cell mass of Setdb1 (KMT1E)-null embryos 
(Dodge et al., 2004). The reason was the homozygous mutations of Eset resulted in peri-
implantation lethality between E3.5 and E5.5. It was possible to investigate the function of 
KMT1E in ES cells with generation of ES cells in which the Setdb1 gene is conditionally ablated 
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by tamoxifen treatment using the Cre/loxP recombination system (Lohmann et al., 2010). In this 
report, KMT1E deficiency in ES cells resulted in derepression of genes controlling 
trophectoderm including as Cdx2 and Hand1 wherease pluripotency genes such as Nanog, Sox2 
and Oct4 and ES cell self-renewal were downregulated. 
Lastly, in vitro ES cells differentiation systems can be used for pharmacological or toxicological 
screening, as somatic cells differentiated from ES cells can react like the organs in vivo. For 
instance, cardiomyocytes derived from ES cells can be used to test cardiotoxicity of substances 
(Reviewed in Davila et al., 2004).  
Even though ES cells have the capacity to differentiate to somatic cells, often the final 
populations of the differentiated cells are not pure and uniform. In addition differentiation 
protocols are often time consuming and complicated. Often sorting protocols for precursor cells 
are included. These are major limitations of in vitro ES cells differentiation to standardized high-
throughput studies. The elucidation of a direct differentiation driver can solve some of these 
problems. In this thesis small molecules were taken as a tool to drive ES cells differentiation to 
defined skeletal muscle cells.  
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Figure Stem Cell Biology and Therapeutics.  
Chemical approaches are applied in vitro and in vivo to manipulate cell 
fate toward desired therapeutic applications including cell expansion, 
differentiation (Adapted fom Li et al., 2013).  
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1.3.3 Small molecule screening system in EB 
Small molecules are chemicals which are less than 1000 Da. They have the possibility of free 
diffusion to the cell membrane. And they possess unique advantages compared to growth factors 
as a therapy and research tools (Reviewed in Lo et al., 2014). As a biomedical research tool, 
taking small molecules is useful due to its easy temporal control. The effects of small molecules 
are mostly rapid and reversible and can be fine-tuned by controlling concentrations and 
combinations (Reviewed in Li et al., 2013). Compared to protein agents, small molecules have 
relatively simple storage and quality control requirements. They are cheaper to buy or to produce. 
These distinct advantages of small molecules allow flexible regulation of complicated signaling 
networks. However, small molecule methodologies are not flawless. For instance, off target 
effects of small molecules can be problematic because they can affect proteins with a similar 
conformation.  
Small molecules based methodologies are facilitating the development of regenerative medicines. 
Therefore they are getting more and more important as a cell fate regulator.  A molecule that was 
found from a screening can also provide fundamental information about uncovered biology. For 
example, (-)-indolactam V (ILV) was identified as an inducer of pancreatic progenitors from 
human ES cells. In that screening, around 5000 compounds that are already known signaling 
pathway regulators and kinase inhibitors were tested (Chen et al., 2009b). Studying the 
mechanism of ILV’s action provided information that activating protein kinase C (PKC) induces 
beta-cell differentiation from human ES cells which was not known before. Small molecules 
which direct the differentiation of pluripotent stem cells to a defined somatic lineage will be 
described below in detail.  
      1.3.4 Example of small molecules as differentiation inducers identified from screening 
• Wnt pathway inhibitors for cardiomyocyte induction 
The extensive effort to obtain cardiac muscle from ES cells reported several molecules inhibiting 
Wnt pathway. From a screening in human ES cells with around 500 pathway modulators, IWP-1 
was discovered as a hit for cardiac muscle differentiation (Willems et al., 2011). A small 
molecule XAV939 which inhibits Wnt signaling also induced cardiac muscle from mouse ES 
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cells (Wang et al., 2011). The time window for Wnt inhibition leading to cardiomyocytes 
induction is critical, suggesting temporal control is very important for differentiation. For 
example, Wnt pathway inhibition between at EB day 3 and 5 pronounced 95.2% EB beating. 
However, Wnt pathway inhibition between at day 3 and 4 showed only 8.3% beating mouse EBs. 
(Wang et al., 2011). From human ES cells, the addition of Wnt pathway inhibitors at day 4 
showed the maximal cardiac induction (Willems et al., 2011). 
Crescent, a member of the sFRP (Secreted Frizzled-related protein, Wnt antagonists) family, was 
also identified from a screen for heart inducers (Marvin et al., 2001). Crescent is expressed in 
anterior endoderm during development of chick embryo. The expression of Crescent is restricted 
to anterior endoderm and complementary to Wnt3a and Wnt8c, the homolog of human and 
mouse Wnt8. When Wnt3a or Wnt8c was overexpressed in anterior mesoderm which is normally 
differentiated to heart, the formation of heart was blocked and the promotion to blood cell fates 
was shown. The transgenic mouse which overexpresses Wnt8c had the phenotype of absent or 
reduced in size of heart (Popperl et al., 1997). These reports suggest that Wnt activity is involved 
in determination of the fate between blood cells and heart formation in posterior and anterior 
region, respectively. The Wnt pathway inhibitors’ activity inducing cardiac muscle from ES cells 
is in line with developmental background.  
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• Inducer of type II TGF-beta receptor degration-1 (ITD-1) for cardiomyocyte 
induction 
A TGF-beta receptor degrading molecule was identified as a driver of ES cells to cardiac muscle 
lineage (Willems et al., 2011). The direct target of ITD-1 is not identified but it was found to 
inhibit the TGF-beta pathway specifically. It induces degradation of TGF-beta receptors via 
proteasome’s action. When ITD-1 was treated at an early stage of differentiation before 
mesoderm was formed, mesoderm formation was inhibited. As a result the effect driving to 
cardiac muscle was blocked. Instead it enhanced differentiation of ES cells to neuro-ectodermal 
fate. This molecule, ITD-1 is effective only when it was treated after mesoderm formation. It 
suggests that TGF-beta signaling inhibits the specification step from progenitors to cardiac 
muscle.  
• Stauprimide for the augmentation of directed differentiation 
Stauprimide is reported to enhance and prime the directed differentiation of ES cells to multiple 
lineages with synergy manner to the cue provided in culture (Zhu et al., 2009). Initially this 
compound was screened by a high-content imaging screening for definitive endoderm 
differentiation. Approximately 20,000 compounds from a kinase-oriented library were tested by 
a fluorescent Sox17 antibody staining. Sox17 is a transcription factor expressed specifically in 
the endoderm (Qu et al., 2008). By using streptavidin immobilized on agarose beads, they tried 
pull-down analysis in order to identify the binding targets of active analogue with linker. Mass 
spectroscopy identified the protein, NME2 (Nonmetastatic cells, protein expressed in-2) which is 
also known as PUF (a c-Myc transcription factor). Indeed Stauprimide repressed c-Myc 
expression in ES cells by inhibiting the nuclear localization of NME2. Repression of c-Myc 
expression by Stauprimide promotes ES cells differentiation.  
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1.3.5 Skeletal muscle differentiation from ES cells up to date 
 
1) Genetic tools 
It was reported that ectopic overexpression of Pax3 in mouse ES cells was sufficient to obtain 
skeletal muscle (Darabi et al., 2008). Similarly, in human ES cells overexpression of Pax7, a 
homolog of Pax3, showed induction of skeletal muscle (Darabi et al., 2012). Both Pax3 and Pax7 
can grant and guide the skeletal muscle lineage in paraxial mesoderm. They also proved that 
induced skeletal muscle by Pax3 and Pax7 overexpression could ameliorate symptoms in 
muscular disease model such as CTX (Cardiotoxin) injected mice and dystrophic mice by 
transplantation.  
Recently the group which published skeletal muscle differentiation from embryonic stem cells by 
Pax3 overexpression identified the function of Pax3 in paraxial mesoderm development and 
myogenesis (Magli et al., 2013). By sorting with surface markers for paraxial mesoderm, 
PDGFRalpha+FLK-1-, they concluded that Pax3 induces the myogenic program in the cell 
population which is already differentiated to the mesodermal lineage. They also identified the 
domain which is essential for function of Pax3. Pax3 protein consists of paired domain, 
homeodomain and transactivation domain. Deletion mutant analysis of Pax3 protein revealed 
that carboxy-terminal part of the paired domain is essential for Pax3 activity.  
2) Biochemicals 
• Retinoic Acid 
Incubation with low concentration of RA (retinoic acid, 25nM) during mouse EB differentiation 
enhances the skeletal muscle differentiation (Kennedy et al., 2009). It was shown that RA 
receptors bind to the regulatory region of Meox1, Pax3 and Wnt3a genes. At the same time, RA 
abrogates the inhibitory activity of BMP4 on skeletal myogenesis by downregulating BMP4 
expression and upregulating Tob1, which is an inhibitor of BMP4. Induction of Pax3 by RA 
turns on the myogenic program and upregulates myogenic regulatory factors. A genetically 
modified cell line which contains a dominant negative beta-catenin/engrailed repressor fusion 
protein did not react to RA addition. It suggests that RA acts through Wnt signaling in this 
differentiation protocol.  
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Likewise, RA incubation increases the percentage of skeletal muscle from human ES cells (Ryan 
et al., 2012). By treating RA in human ES differentiation, the duration of differentiation to 
skeletal muscle was shortened. Considering the difference in gestation time between mouse and 
human, this group compared and established the timeline of myogenic differentiation from 
mouse and human ES cells by RA. The duration until mesoderm and premyogenic mesoderm is 
similar in mouse and human ES cells but it takes longer time in human ES cells differentiation 
for myoblast and muscle formation. But the efficiency of myogenesis by RA is low. It requires 
further effort and improvement to obtain a better protocol for skeletal muscle differentiation 
from ES cells. 
• Wnt pathway activators for skeletal muscle 
In ES cells differentiation, Wnt signaling has a different action on cardiac and skeletal muscle 
differentiations. For cardiac muscle induction from human and mouse ES cells, inhibition of Wnt 
is positively effective. In contrast, Wnt activation is enhancing the skeletal muscle differentiation 
from ES cells. Wnt pathway activation by GSK3beta inhibitor induces paraxial mesoderm and 
activates the myogenic program in human ES culture system (Borchin et al., 2013). Recently 
another publication which was carried out with zebrafish embryos also showed that Wnt 
activation drives them to skeletal muscle lineage (Xu et al., 2013). This group conducted a 
screening using dissociated zebrafish embryo in order to identify molecules inducing skeletal 
muscle. A combination of chemicals (basic FGF, BIO and Forskolin) enhances the skeletal 
muscle differentiation in zebrafish embryos. And this combination also works in mouse and 
human iPS cells for skeletal muscle differentiation showing conserved activities across species. 
They also found a set of compounds which block the differentiation of muscle progenitors into 
mature muscle cells, for example, p38 pathway inhibitors. Previously it was reported that p38 
pathway is required for muscle formation (Wu et al., 2000). Those studies imitated the 
knowledge from embryo development. For skeletal muscle progenitors during development, 
dorsal neuroepithelial and neural crest cells send the differentiation cues like Wnt signal for 
patterning of paraxial mesoderm.  
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Objective of the Thesis 
 
To identify small molecules which drive embryonic stem cell differentiation to skeletal 
muscle with a high efficiency 
Up to date the protocols known for skeletal muscle differentiation from embryonic stem cells are 
labor intensive, not very efficient and slow. In my Ph.D. thesis, I aimed to identify low molecular 
weight compounds which can enhance the efficiency and speed up the differentiation to skeletal 
muscle differentiation from mouse embryonic stem cells. The rational of the small molecule 
screening was set up based on the literature and known findings about mouse embryo 
development and embryonic stem cell differentiation. Pax3 transcription factor was known as the 
first markers of skeletal muscle during embryonic stem cell differentiation. Therefore I aimed to 
find small molecules which induce the level of Pax3 during mouse embryonic stem cells 
differentiation.   
 
To elucidate the mechanism of action of a small molecule and provide pathways involved in 
embryonic skeletal muscle differentiation 
Dissecting molecular pathways that are involved in ES cell derived skeletal muscle 
differentiation can provide critical information about the developmental process toward skeletal 
muscle. Since embryonic stem cell differentiation often recapitulates the development process, 
taking this cellular system can help to understand the complex system of embryo development. It 
will also help to transfer the protocol which modulates pathways from mouse ES cells to human 
ES cells once we know the mechanism of actions of a highly active small molecule. In this thesis 
I focused on identifying the mechanisms involved in skeletal muscle differentiation from mouse 
embryonic stem cells. The approach was based on a comparison at the mRNA and microRNA 
level during embryonic skeletal muscle differentiation with and without a small molecule. 
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Abstract: 
The multi-lineage differentiation capacity of mouse and human embryonic stem (ES) cells offers 
a testing platform for small molecules that mediate mammalian lineage determination and 
cellular specialization. Here we report the identification of a small molecule which drives mouse 
ES cell differentiation to skeletal muscle with high efficiency without any genetic modification. 
Mouse embryoid bodies (EBs) were used to screen a library of 1,000 small molecules to identify 
compounds capable of inducing high levels of Pax3 mRNA. Stimulation of EBs with SMIs 
(Skeletal Muscle Inducer, SMI1 and SMI2) from the screen resulted in a high percentage of 
intensively twitching skeletal muscle fibers three weeks after induction. Gene expression 
profiling studies that were carried out for Mode of Actions (MoA) analysis showed that SMIs 
activated genes regulated by the Wnt pathway, and inhibited expression of Smad2/3 and Sonic 
Hedgehog target genes. A combination of three small molecules known to modulate these three 
pathways acted similarly to the SMIs found here, driving ES cells to skeletal muscle. Taken 
together, these data demonstrate that the SMI drives ES cells to skeletal muscle via concerted 
activation of the Wnt pathway, and inhibition of Smad2/3 signaling and Sonic Hedgehog (Shh) 
pathways. This provides important developmental biological information about skeletal muscle 
differentiation from embryonic stem cells and may lead to the development of new therapeutics 
for muscle disease. 
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Introduction: 
Many drug discovery programs use cell-based assays for hit identification based on 
disease specific phenotypes. Embryonic stem (ES) cells or induced pluripotent stem (iPS) cells 
which can be differentiated into almost all cell types of the body may help to generate cells that 
are primarily affected by the disease and often can only be isolated from live animals or humans. 
Characterization of these cells may yield information about the signals and mechanisms of these 
diseases and could lead to new targets and drugs for therapy. Thus, there are considerable efforts 
in adopting stem cell assays for drug discovery (Tabar and Studer, 2014). However, in the case 
of ES cells this approach is still limited by the availability of effective differentiation protocols 
for specific cell types.  
In embryogenesis, all skeletal muscles except for those of the head are derived from the 
somites. Somites are located adjacent to the neural tube and notochord and are transient, 
segmentally organized structures which contain the paraxial mesoderm. Signals from these 
structures trigger the somite to form the sclerotome, and the dermomyotome, thus giving rise to 
the generation of the dermis and muscle (Bentzinger et al., 2012). Cells expressing the 
transcription factor Pax3 in the dermomyotome migrate medially through the dorsomedial lip of 
the dermomyotome to form an epithelial sheet, known as the myotome (Goulding et al., 1991). 
Myogenesis occurs at this site upon activation of myogenic regulatory factor (MRF) genes, 
including; Myod1, Myf5, Mrf4 and Myog (Pownall et al., 2002). While Myf5 and MyoD 
activate muscle-specific gene expression and commit the progenitor cells into skeletal muscle 
lineage, myogenin and Mrf4 largely regulates  late stage myogenic differentiation, such as the 
fusion of myoblasts into myotubes (Darabi and Perlingeiro, 2008). Wnt and Shh signaling, from 
the dorsal neural tube and notochord  respectively, act as the positive regulators of Myf5 gene 
expression; whereas MyoD gene expression depends on Pax3 and Myf5 (Bryson-Richardson and 
Currie, 2008). Several groups have demonstrated the role of Pax3 in myogenesis where it 
activates upstream of MRFs (Magli et al., 2013). Pax7, a homologue of Pax3, also marks cells of 
the dermomyotome as well as satellite - the stem cells of the muscle (Jostes et al., 1990). Current 
methods for the generation of skeletal muscle cells from pluripotent stem cells include treating 
the cell with small molecules or over-expression of master regulatory genes such as MyoD or 
Pax3. Differentiation of the skeletal muscle by retinoic acid that upregulates Pax3 and MyoD is 
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substantially low in mouse and human ES cells (Kennedy et al., 2009; Ryan et al., 2012), 
whereas directed differentiation with Pax3 or Myf5 is more efficient but requires each desired 
line to be engineered for transgene expression which is slow, labor intensive and may interfere 
with other genes (Darabi et al., 2008; Iacovino et al., 2011).  
However, protocols to proficiently produce specific cell types from ES cells with either 
small molecules identified by screening or by guided differentiation using multistep cell culture 
procedures do not currently exist for muscle (Chambers et al., 2009; Kattman et al., 2011; Shan 
et al., 2013). Therefore we designed a screen to identify small molecules that could induce 
skeletal muscle differentiation from ES cells. Based on the finding that Pax3 overexpression is 
sufficient to induce skeletal muscle from mouse ES cells (Darabi et al., 2008), we aimed to 
identify small molecules which induced Pax3 mRNA during mouse EB differentiation leading to 
subsequent skeletal muscle differentiation. In this study we describe, a small molecule potent 
inducer for skeletal muscle differentiation from mouse embryonic stem cells. Further, we could 
mimic its action by adding small molecules modulating well known development pathways. 
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Materials and Methods: 
Cell Culture and Reagents  
Mouse embryonic stem cells were cultured in Knock-Out Dulbecco’s modified Eagle’s 
medium  (DMEM) (Ambion/ Life Technologies/ Gibco/ Invitrogen, Carlsbad, CA, 
http://www.invitrogen.com/site/us/en/home.html) supplemented with 15% of FBS (Biowest, 
Nuaillé, France http://www.biowest.net/), 1% penicillin/streptomycin (Gibco), 2 mM Glutamine 
(Gibco), 0.1 mM β-mercaptoethanol (Gibco), 1,000 U/ml leukemia inhibitory factor (LIF) (1000 
U/ml ‘‘ESGRO’’, Millipore, Billerica, MA, http://www.millipore.com) and 3i compounds (3 µM 
CHIR99021, 0.8 µM PD184352, and 0.1 µM PD173074) (Sigma, St. Louis, MO, 
http://www.sigmaaldrich.com/sigma-aldrich/home.html) on gelatin-coated plate. Embryoid body 
(EB) was formed in differentiation medium containing Iscove’s Modified Dulbecco’s Medium 
(Sigma) supplemented with 10% FBS, 1% penicillin/streptomycin (Gibco), 2mM Glutamine 
(Gibco), 1% Insulin-Transferrin-Selenium (Invitrogen) in ultra-low-attachment (ULA) plate 
(Corning Costar, Corning, NY, http://www.corning.com). The number of cells for EB formation 
was controlled as 1,000cells/ml for 96-well format and 200,000cells/ml for 6-well format. SMI’s 
were added at EB day 1 as well as at day 4 when EBs were transferred on 0.1% gelatin-coated 
plates. If not other indicated the concentration used for SMI1 and 2 was 10µM. From day 4, EB 
was maintained in differentiation medium which was changed every other day. Activin A (R&D, 
Minneapolis, MN, http://www.rndsystems.com,) was used at 50ng/ml, IWP3 (Stemgent, 
Cambridge, MA, https://www.stemgent.com/) at 10µM and Hh-Ag1.5 was added at 1µM. 
Differentiation to skeletal muscle with pathway inhibitors was carried out with 2.5µM SB431542 
(Stemgent), 0.5µM BIO (Calbiochem/ Merck Millipore, Darmstadt, Germany, 
https://www.emdmillipore.com/index.do) and 10µM NVP-LDE225. All the three compounds 
were added at EB day 4. SB431542 was incubated for 2 days. Both BIO and NVP-LDE225 were 
incubated until EB day4+6. 
 
Embryoid body screen 
500 ES cells were dispensed in 0.1ml of DM medium into a well of a 96-well ULA plate 
and incubated at 37°C and 5% CO2. Next day, EB formation was controlled by imaging with 
Cellavista. 80µl of fresh medium was added to the well, then 20µl compound was added to have 
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a final compound concentration of 10µM. All samples were in duplicate. At day 4 EBs were 
transferred by a Hamilton robot to normal tissue culture 96-well plates (Nunc/ Thermo Fisher 
Scientific, Waltham, MA, http://www.thermofisher.com/en/home.html, 167008) coated for one 
hour with 50µl of 0.1% gelatin (Sigma, G1890). Three days later one replica was washed with 
PBS and frozen at -80°C for RNA analysis. For the second replica medium (0.2 ml) was changed 
every other day. At day 4+12 visual examination for skeletal muscle was performed. For mRNA 
quantification the frozen plate was slowly thawed on ice and then washed with 60µl of FCW 
buffer from FastLane kit (Qiagen, Hilden, Germany, http://www.qiagen.com/default.aspx). 
Before lysis the FCW buffer was completely removed and then 25 µl of cell processing mix 
(23.5 µl FCPL + 1.5 µl Wipeout Buffer 2 from FastLane kit) was added. The plate was incubated 
for 10 min at room temperature with gentle shaking on a plate shaker. Afterwards the lysate was 
transferred to a PCR (Polymerase Chain Reaction) plate containing 25 µl RNase-free water and 
heated up for 5 min at 75°C and before it was briefly centrifuged. Immediately thereafter the 
reverse transcription (RT) and PCR reactions were initiated or the plate was stored at -80°C. For 
RT-PCR 2µl of lysate was mixed with 5µl of mastermix from Fast Lane kit, 0.25µl TaqMan 
assays-on-demand Pax3 (Applied biosystems, Foster City, CA, 
http://www.appliedbiosystems.com/absite/us/en/home.html), 0.25µl TaqMan assays-on-demand 
20x GAPDH (Applied Biosystems), 0.1 µl RT mix from FastLane kit and 2.4 µl H2O. For the 
RT-PCR a 7900HT AB instrument (Applied Biosystems) was used with the following program 
1x20min at 50°C; 1x15min at 95°C ; 40x (45sec at 94°C, 45sec at 60°C).  
 
Generation of Pax7 ES cells 
The mouse Pax7 11.9kb sequence containing exon 8 and exon 9 until STOP codon was 
amplified by PCR from C57Bl/6 mouse genomic DNA together with a 3.8kb 3’ arm containing 
the 3’ end of exon 9 from STOP codon. Both arms were cloned into pRAY neomycin vector 
resulting in the targeting vector. Ires luciferase cassette was then integrated within exon 9 exactly 
downstream of the STOP codon. Sequences were compared to sequences available from the 
Ensembl database (Ensembl Gene ID ENSMUSG00000028736). Homologous recombination 
was done in 129S4 ES cell culture by electroporation of 20 µg of the linearized targeting 
plasmid. Transfected ES cells were selected for neomycin resistance (0.2 mg/ml G418 
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(Gibco#10131-019) the day after transfection. 300 neo-resistant ES cell clones were isolated and 
analyzed by PCR for homologous recombination as well as southern blot for the correct 
integration.  
 
Luciferase Assay 
Envision plate reader (Perkin Elmer, Waltham, MA, 
http://www.perkinelmer.com/default.xhtml) was used to measure luminescence levels of 
Luciferase via Steady-Glo kit (Promega, Madison,WI, http://www.promega.com) from 
differentiated EBs according to the manufacturer’s recommendations. FireFly luciferase 
activities were normalized to the cell viability measured at the beginning with Resazurin.  
 
Flow Cytometry Analysis 
EBs were dissociated by TrypLE Express (Life Technologies) for 30 min at 37°C and 
fixed by 4% paraformaldehyde for 10 min. Single cells were incubated for 1 hour with Pax3-PE 
(R&D Systems, IC2457P, 1:50 dilution) after permeabilization with 0.1% Tween-20 in PBS. 
Flow cytometry analysis was done with CyAn ADP Analyzer (Beckman Coulter, High 
Wycombe, UK, https://www.beckmancoulter.com). 
 
Reverse Transcription quantitative PCR 
Total RNA was extracted from differentiated EBs at indicated time points with Trizol 
(Invitrogen) according to the manufacturer’s instructions. RNA concentration was determined by 
Nanodrop and reverse transcription was done with 500ng of total RNA by Reverse Transcription 
kit (Applied Biosystems). qPCR reactions were carried out on a 9600 (Applied Biosystems) with 
TaqMan mastermix (Applied Biosystems). mRNA levels were normalized to levels of GAPDH 
mRNA in each sample. TaqMan Probes for PCR were purchased from Applied Biosystems (See 
Supporting Information Table S1).  
 
Immunocytochemistry 
For Pax3 staining from EB, paraffin section staining was carried out after embedding EBs 
to agarose and paraffin. Differentiated EBs were fixated with 4% paraformaldehyde and 
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permeabilized with 0.2% Triton X-100 in PBS followed by citrate buffer antigen retrieval using 
the Citrate Buffer Concentrate pH 6.0 (Quartett Immunodiagnostika, Berlin, Germany, 
http://www.quartett.com/). Pax3 antibody supernatant (DSHB, Iowa City, IA, 
http://dshb.biology.uiowa.edu/, 1:50 dilution) was incubated overnight at 4°C. Prior to 
incubation with primary Myogenin (DAKO, Glostrup, Denmark, www.dako.com, M3559, 1:200 
dilution) and MHC (Merck Millipore, 05-716, 1:500 dilution) antibodies, EBs were incubated 
with blocking solution containing normal goat serum. Incubation with detection antibodies 
labeled with Alexa 594(Invitrogen) or Texas Red (Invitrogen) was followed by DAPI 
(Promokine, Heidelberg, Germany, http://www.promokine.info/) staining. 
 
Immunoblot Antibodies 
For immunoblot assay for phosphorylation of Smad proteins, EBs were differentiated in 6 
well ULA plate (Corning) with 200,000 cells/ml concentration. 10µM SB431542 was treated at 
EB day 1 to inhibit the phosphorylation of Smad proteins. Protein lysate at the indicated time 
point was prepared with RIPA buffer (Rockland, Gilbertsville, PA, http://www.rockland-
inc.com/Default.aspx). Antibodies used include phospho-Smad2 (Merck Millipore, AB3849), 
phospho-Smad3 (Merck Millipore, 04-1042), Pax3 (DSHB, Univeristy of Iowa) and GAPDH 
(Ambion, AM4300). 
 
Microarray processing and data analysis 
RNA samples were subjected to microarray analysis on Affymetrix GeneChip Mouse 
Genome 430 2.0 chips (Affymetrix) according to the manufacturer's recommendations. All 
statistical analyses were performed using R/Bioconductor (www.bioconductor.org). Quality 
control was performed using both AffyQCreport and arrayQCmetrics packages. Data was Robust 
Multichip Average (RMA) normalized using RMA and scaled to a 2% trimmed mean of 150. 
Probes with normalized expression values below 50 in 75% of samples were filtered out. 
Differential gene expression was performed using a linear model approach (Limma). Genes with 
a fold change higher than 2 and a P-value below 0.01 (Benjamini and Hochberg multiple testing 
correction) were considered regulated. Gene set enrichment analysis (GSEA) (Subramanian et 
al., 2005), was performed on fold change ranked list of all non-filtered probesets collapsed to 
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gene symbols using Panther Pathway Library and Metacore gene sets databases. GSEA results 
were further analyzed using the enrichment map tool (Merico et al., 2010). GSEA results were 
visualized using Tibco Spotfire.  
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Results: 
EB screening identified skeletal muscle inducers (SMIs) 
To identify factors that permit skeletal muscle formation from mouse ES cells, we 
designed a screen based on embryoid body differentiation. Because EB spontaneously 
differentiates into the three germlayers, they may represent an efficient system to identify 
specific compounds which can influence this differentiation process. The readouts in our screen 
for skeletal muscle induction were; Pax3 mRNA upregulation at an early time point (d4+3) and 
the occurrence of skeletal morphology by visual examination at a later time point (d4+12). As a 
consequence the screen was performed in duplicate to have both readouts. EB formation was 
carried out using ULA (Ultra Low Attachment) culture plates with 500 dissociated ES cells per 
well in suspension culture. Compounds, as a 10 µM solution in DMSO, were added at day 1. EB 
size measurement demonstrated a very low ‘well-to-well’ variation during the first 4 days (Fig. 
S1). As EB size became more variable from day 4, we transferred the EB at day 4 to gelatin-
coated culture plates for further differentiation. Three days later from transfer (d4+3) Pax3 and 
GAPDH (for normalization) mRNA levels were measured in the first replica by Real-Time RT- 
multiplex PCR. In the second replica, skeletal muscle formation was evaluated by visual 
inspection followed by MHC (Myosin Heavy Chain) staining at day 4+12. Out of 968 small 
molecules tested, 18 compounds increased Pax3 RNA more than 6 fold (Fig. 1A). Six 
compounds induced both Pax3 mRNA and skeletal muscle morphology. However, only one 
compound showed a dose dependent induction of Pax3 mRNA. Further validation showed that 
N-[4-(trifluoromethyl)-6-methoxymethyl-2-pyrimidinyl]-N-(2-methyl-6-nitrophenyl)-urea ( 
called Skeletal Muscle Inducer 1 (SMI1)) was also the most potent inducer of skeletal muscle 
(Fig. 1B) with an EC50 of 8 µM (Fig. 1C). Structure-activity relation experiments for SMI1 
identified SMI2, a N-methyl-pyrimidinyl analogue, that exhibited 30% higher induction of 
skeletal mRNA markers compared to its parent compound (Fig. 1B). Interestingly, the EC50 of 
SMI2 was not significantly increased (Fig. 1C).  
The increase of Pax3 was also further confirmed by Immunofluorescence staining for 
Pax3 of 8 day old EBs (Fig. 1D) and by FACS analyses (Fig. 1E). Cells treated with SMI1 
showed about 15 to 20% Pax3 positive cells whereas untreated control showed around 1%. To 
confirm skeletal muscle lineage commitment additional muscle markers were analyzed. First 
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induction of the satellite cell marker, Pax7, was examined using an ES Cell line containing a 
Luciferase coding region inserted into the endogenous Pax7 gene’s 3’-UTR. SMI1 induced a 
time dependent increase of Pax7-luciferase expression starting at day 4+2 with a peak at day 4+7 
(Fig. 2A). At day 4+4 MyoD, Myf5 and Myogenin demonstrates the presence of fully developed 
skeletal muscle. SMI1 induced significant increase in MyoD, Myogenin and Myf5 mRNAs (Fig 
2B and S2). Induction of a muscle phenotype was confirmed by immunofluorescence staining 
staining for Myogenin and skeletal MHC (Fig 2C) and by the spontaneous contraction at later 
time points, which demonstrates the presence of a functional contraction apparatus (Movie 1). 
The kinetics of mRNA expression shows the expected order of the different markers. Pax3 and 
Pax7 were first detected at day 4+1 followed by MyoD, Myogenin and Myf5 at day 4+5 (Fig. 
S2). To quantify the percentage of skeletal muscle at the end of differentiation we used an 
indirect measurement based on the area which stains positive in immunofluorescence staining for 
MHC three weeks after the initiation. The percentage varied between EB, although often up to 
100% of the cell area stained positive for MHC when treated with SMIs whereas in DMSO 
treated controls only in very rare cases positive cells were found (Fig. 2D; Fig.S7). Interestingly, 
we found very often beside skeletal muscle fibers also adipocytes (Fig. S3). 
 
Comprehensive gene expression level study  
In order to better understand the mechanism of action of SMI, we performed gene 
expression analysis with mRNA samples of three independent experiments from undifferentiated 
mouse ES cells and differentiated mouse EBs at day 4 and day 4+4, either in presence or absence 
of SMI1. Using Affymetrix expression arrays, 68 genes (d4) and 569 genes (d4+4) were 
expressed differentially by SMI1 treatment at a threshold of fold change more than 4 and a p-
value less than 0.05 (Supporting Information Table S2). As expected, pluripotency genes, such 
as Nanog, Oct4, Sox2, Rex1 and Klf4 (Takahashi and Yamanaka, 2006), were downregulated as 
ES cells progressed towards differentiation in both groups (Fig. S4). However, the pluripotency 
genes were not differentially regulated by SMI1 treatment compared to control. Among the most 
upregulated genes after day 4+4 from SMI1 treatment we found Pax3 and Pax7 as well as the 
myogenic regulatory factor MyoD and Myogenin (Supporting Information Table S2).  
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In order to explain and understand the MoA induced by SMI1, we performed a Gene Set 
Enrichment Analysis (GSEA) for day 4 and day 4+4 time points (Supporting Information Table 
S3). Using the Panther Pathway Library and Metacore gene sets databases a number of pathways 
linked to development process like ectoderm development (Bessarabova et al., 2012; Thomas et 
al., 2003) were differentially expressed in SMI1 treated samples compared to the control group. 
Interestingly at day 4 the Wnt pathway was clearly upregulated. Therefore we looked at Wnt 
pathway and its target genes more carefully. From 82 genes categorized as part of the Wnt 
pathway, 9 genes were upregulated more than 2 fold and only 2 genes were negatively regulated 
more than 2 fold in EBs at day 4 after SMI1 treatment (Supporting Information Table S4). Out of 
13 Wnt target genes, 5 genes were significantly induced more than 2-fold compared to the 
untreated control group (Fig. 3A). The strong regulation of sets of genes related to Wnt pathway 
is consistent with the critical role of Wnt activation during embryonic skeletal muscle 
differentiation (Aulehla and Pourquie, 2010). It has been shown that canonical Wnt activation is 
an initial step to induce skeletal muscle developed from paraxial mesoderm. Other well-known 
developmental pathways were negatively regulated by SMI1, including the Nodal Pathway at 
day 4 and the Sonic Hedgehog pathway at day 4+4. At EB day 4, GSEA analysis revealed that 
many gene sets involved in Nodal signaling in early mesendoderm formation were 
downregulated in the SMI1 treated group. At day 4+4, the number of gene sets involved in 
hedgehog signaling in medulloblastoma stem cells was reduced. Strikingly, Shh itself was one of 
the most down regulated genes (Supporting Information Table S2). Based on these findings we 
hypothesized that Wnt pathway, Nodal pathway and Sonic hedgehog signaling play a significant 
part in the skeletal formation out of mouse EB formation induced by the SMI. 
 
Dependency of Wnt activation during SMI’s action 
To validate if the Wnt pathway plays a major role in SMI’s action, we measured the 
mRNA level via Real-time RT-PCR analyses of Brachyury T (BraT), Mesogenin1 and Axin2, 
that are known as important Wnt signaling outputs during development (Aulehla and Pourquie, 
2010). SMI stimulation was indeed increasing the level of BraT and Axin 2 as well as 
Mesogenin1, which is a key player for genesis of the paraxial mesoderm at either EB day 3 or 4 
(Fig. 3B) (Fior et al., 2012). To further validate if SMI’s action is dependent on Wnt pathway 
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activation, EBs were differentiated together with an inhibitor of the Wnt pathway, IWP3 (Chen 
et al., 2009a; Willems et al., 2011). As expected, EB differentiation toward skeletal muscle 
lineage was effectively inhibited. After co-treatment with IWB3 none of the skeletal myogenic 
genes, Pax3, MyoD, Myf5 and Myogenin were upregulated in EB day 4+4 (Fig. 3C) cultures, 
whereas Nkx2-5 which is a key transcription factor for the cardiac differentiation was not 
affected (Fig. S5A). To further confirm the effect of Wnt pathway inhibition during SMI1’s 
action, we examined the activity on a Pax7 Luciferase knock-in ES cell line. Intriguingly the 
level of Pax7 Luciferase was completely downregulated by Wnt pathway inhibition when added 
together with SMI2 (Fig. 3D). Based on these findings we conclude that Wnt activation was a 
key event of SMI’s action for skeletal formation of ES cells. However, addition of BIO, a Wnt 
pathway activator, did not stimulate skeletal muscle differentiation (Fig. S5B).  Thus, we 
speculate that additional pathways must also be necessary for the action of SMI.  
 
Nodal pathway is involved in SMI’s action 
GSEA at day 4 indicated that SMI1 affected the Nodal pathway in EBs at day 4. Indeed 4 
genes (Cer1, Gsc, Eomes1 and Otx2) which are described as members of the Nodal pathway 
were among the top 12 downregulated genes in SMI1 treated EBs at day 4 (Fig. 4A, 4B, 
Supporting Information Table S2) (Liu et al., 2011). Smad signaling led by Nodal/Activin has 
been known to be involved in ES cell propagation (Ogawa et al., 2007). In addition, the signal 
gradient of Nodal/Activin pathway is an important factor for cell fate decisions between 
mesendoderm and trophectoderm lineages (Lee et al., 2011). These data suggested that Smad 
signaling might be affected by SMI1 addition. Indeed, phosphorylation level on Smad2/3 
proteins in EBs at day 4 was moderately decreased 3 days after SMI1 addition (Fig. 4C). To 
elucidate if the decrease of Smad signaling is critical for SMI1 action, we tested EB 
differentiation in presence of both SMI1 and Activin A. When Smad signaling was activated by 
Activin A together with SMI1, the differentiation to skeletal muscle lineage was inhibited. 
mRNA levels of Myogenin at EB day 4+4 was dramatically reduced by Activin A treatment (Fig. 
4D). These observations are consistent with inhibition of Nodal/Activin signaling being part of 
skeletal muscle differentiation by SMI. 
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Sonic Hedgehog activation inhibits SMI’s action 
GSEA analysis of the microarray data at day 4+4 revealed that the majority of genes 
belonging to Sonic Hedgehog transcriptional signatures were significantly downregulated during 
differentiation induced by SMI1 (Fig. 5A). Confirmation experiments by Real-time RT-PCR for 
key components of the Shh pathway (Shh, Gli and Ptch) showed that expression of all tested 
genes was dramatically decreased by SMI1 (Fig. 5B). In order to further validate the function of 
Shh pathway during SMI action, we differentiated EBs with SMI2 and the well characterized 
Smo agonist Hh-Ag1.5 (Frank-Kamenetsky et al., 2002). As expected the inducing effect on 
mRNA of Pax3, MyoD, Myf5 and Myogenin by SMI2 was dramatically decreased when the 
Smo agonist was added to EBs at day 4 together with SMI2 (Fig. 5C). Likewise, increase of 
Pax7 reporter Luciferase activity by SMI2 was blocked by adding Smo agonist Hh-Ag1.5 (Fig. 
5D). Based on these data, we conclude that inhibition of the Shh pathway as well as Wnt and 
Nodal pathway modulation is part of SMI’s induction of skeletal muscle formation. As a 
consequence of this finding we speculated that it should be possible to induce skeletal muscle 
formation by adding compounds which modulate these three pathways.  
 
Mimic of SMI1’s action by small molecule cocktails modifying identified signalings 
The data obtained so far suggest that differentiation of skeletal muscle from ES cells by 
SMI is initiated by Wnt pathway stimulation and Nodal pathway inhibition at an early time point 
followed by Shh signaling inhibition at a later time point. To test this hypothesis the following 
compounds were used: as a stimulator of the Wnt pathway the glycogen synthase kinase-3 
inhibitor (BIO) was selected because of its low toxicity  and as inhibitors of Nodal and Shh the 
Alk4/5/7 inhibitor (SB431542) and the Smo antagonist (NVP-LDE225 also known as   
Erismodegib) were added, respectively (Inman et al., 2002; Pan et al., 2010; Sato et al., 2004; Xu 
et al., 2013). First we tested modulation of each single pathway on skeletal muscle differentiation. 
However, single molecules showed no positive effect on skeletal muscle differentiation (Fig. 
S5B, data not shown). Next we tested the combination of the inhibitors of Smad and Hedghog 
signaling at different time points. Because Nodal inhibition was found earlier than Shh inhibition 
we kept the time point of the addition of NVP-LDE225 constant and varied the time point of 
Nodal inhibition. Indeed, when SB431542 was added to EBs at day 1, where mesoderm was not 
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yet formed (Fig. S6), EB differentiation to skeletal muscle based on mRNA induction was not 
induced whereas addition of SB at day4 showed dramatic Pax7 induction (Fig. 6A; Fig. S6). This 
induction could be further enhanced by adding BIO on top of SB431542 and NVP-LDE225 at 
day 4. Again addition of BIO at day 4 showed the highest synergistic effect with SB431542 and 
NVP-LDE225 (Fig. 6B). Real-time RT-PCR analyses for muscle specific markers as well as 
immunofluorescence staining demonstrate that BIO/SB/LDE (BSL) treatment alone was enough 
for induction of skeletal muscle. Pax3, Pax7 and Myf5 mRNA were significantly induced at EB 
day 4+4 as well as MyoD and MyoG at day 4+8 (Fig. 6C, 6D). Again immunofluorescence 
staining of Myogenin and MHC at day 4+8 and day 4+20 confirmed the skeletal muscle 
induction at later time points (Fig. 6E, S7). Similar to EBs treated with SMIs, intensive twitching 
was observed (Movie 2). Finally, combining SMI1 to the BSL protocol was not an additive 
process (Fig. S8). All these data indicate that SMI1 acts indeed through Wnt, Smad signaling and 
Hedgehog pathway and that BSL treatment could be an alternative way for inducing skeletal 
muscle from mouse ES cells.  
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Discussion: 
Currently available differentiation protocols for the generation of skeletal muscle from 
ES cells are still very labor intensive and often not very efficient. The aim of this study was to 
identify small molecules which can push ES cell differentiation towards skeletal muscle cells.  In 
an initial screen we identified SMI1 as a potent inducer of skeletal muscle differentiation. 
Although the direct target of SMI1 has not yet been identified, the work presented here suggests 
that the SMI acts directly or indirectly by activating Wnt and inhibiting Nodal and Shh pathways. 
Indeed a cocktail of molecules that able to interact directly with these pathways induced 
differentiation of mouse EBs similarly to the SMIs. The method described herein, offers a robust 
and simple methodology for the induction of highly functional skeletal muscle from mouse EBs. 
EBs represent complex, ordered, 3-dimensional structures with the capacity to reproduce 
a number of developmental processes and produce a remarkable number of cell lineages present 
in mature organs. EB differentiation protocols are thought to allow many of the same inductive 
processes that accompany the development of embryonic organs. It is also assumed that many of 
these processes will be similar in adult organ regeneration (Rohwedel et al., 1994). Thus EBs 
may provide a platform to identify genes that can enhance or inhibit lineage commitment and 
expansion in the context of diverse cell-cell interactions that occur in vivo. Our finding that 
activating Wnt and inhibiting Smad2/3 and Shh pathways can push ES cell into the muscle 
lineage is consistent with several in vivo studies. In vertebrate skeletal muscle originates from 
somites where paraxial mesoderm receives the cue for further differentiation to dermomyotome 
from the dorsal neural tube and notochord by many different factors (Bailey et al., 2001). In this 
complex and well-coordinated interplay of various pathways, members of the Wnt family play an 
important role for the formation of the somites and the dermomyotome (Bentzinger et al., 2012). 
Other studies have also found that Wnt activation is indeed a key step for skeletal muscle 
induction in ES cells differentiation (Borchin et al., 2013; Xu et al., 2013). The finding  the 
number of Pax3 positive cells is increased  in Shh deficient embryos from mouse and zebrafish is 
also consistant with our findings that  Shh inhibition increases Pax3 levels in EBs (Borycki et al., 
1999; Feng et al., 2006).  In contrast, the finding that the Nodal/Activin A pathway is involved in 
skeletal muscle formation is at present novel. One explanation for this activity is that 
Nodal/Activin A inhibition acts indirectly by suppression of endoderm formation. Activin A 
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stimulation is normally used to push ES cell into the definitive endoderm. Inhibition of this 
prominent differentiation pathway in EBs could lead to the enhancement of mesoderm formation 
and thereby to an increase of skeletal muscle formation. This explanation is supported by the 
analysis of genes regulated at day 4+4 after SMI induction.  These studies demonstrated that 
Nodal signaling associated with early mesendoderm formation as well as Activin A signaling 
was downregulated whereas early embryonal epaxial and hypaxial myogenesis were enhanced 
by SMI treatment (Supporting Information Table S3).  
The similarity of the EB differentiation to the in vivo development is further supported by 
two observations. During the experiments we realized that SMI as well as BSL were not only 
inducing skeletal muscle but often also adipocytes (Fig. S3). Pathway analysis indeed indicated 
that the brown fat differentiation was induced (Supporting Information Table S3). These data 
imply that the protocol we identified induced a common precursor cell population. Skeletal 
muscle and brown adipocytes have the same differentiation history coming from mesoderm and 
are separated later in development at the stage of mesenchymal stem cells (Gesta et al., 2007). In 
addition we realized that SMI is not only inducing skeletal muscle and adipocytes formation but 
also inhibiting the formation of cardiomyocytes. Normally no beating cardiomyocyte clusters 
were found in the SMI-treated EBs, which was in strong contrast to untreated samples (data not 
shown). This finding was supported by an external finding that Wnt inhibition as well as Alk 2/3 
inhibition by Dorsomorphin or Noggin can enhance the formation of cardiomyocytes (Hao et al., 
2008; Wang et al., 2011). It appears that these differences in signaling are important for 
switching between skeletal and cardiac differentiation.  
Finally, there is considerable interest in creating myogenic precursors for cell based 
therapy in muscle disease such as muscular dystrophy. Darabi and Iacovino et al. have 
demonstrated that expression of Pax3, Pax7 or Myf5 in ES and iPS cells can drive differentiation 
to myogenic precursors that can be transplanted in mice (Darabi et al., 2012; Darabi et al., 2008; 
Iacovino et al., 2011). However, the use of genetically modified ES cells for gene therapy creates 
potential safety issues for ultimate use in patients, which could be eliminated by efficient 
transgene-free differentiation procedures. Although the SMI and BSL procedures described here 
are highly efficient, similar procedures still need to be optimized for human ES and iPS cell 
cultures. Also the ability of chemically induced myogenic cells described here to engraft into 
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adult muscle needs to be determined. If successful this method could provide an efficient, 
scalable transgene free platform for production of myogenic cells for human therapy. 
 
Conclusion 
In this study, we identified two molecules, SMI1+2, which were able to direct the fate of 
differentiating ES cells to skeletal muscle and elucidated their mode of action. It may provide a 
new platform to produce functional skeletal muscle derived from ES cells.  
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Figure legends: 
Figure 1: EB-Screen identified SMI1 as a modifier of skeletal muscle development  
(A) Delta Ct mRNA levels of Pax3 normalized to GAPDH of each compound used in the screen. 
Each row represents a 96 well plate. Threshold was set 2.5 Ct values over the average Ct of 
DMSO treated EBs which are marked with black color. Arrow indicates data for SMI1.   
(B) Structure of SMI1 and its more potent analogue, SMI2. 
(C) Dose-dependent induction of Pax3 mRNA levels by SMI1 and SMI2, normalized to GAPDH 
in mouse EBs measured by Real-time RT-PCR. The bars indicate standard deviation for 3 
independent EBs from a representative experiment. 
(D) Immunofluorescence staining for Pax3 expression on a section of an eight day old EB treated 
with SMI1 compared to untreated control. Scale bar indicates 80 µm. 
(E) Representative flow cytometry analysis with an antibody against Pax3 of dissociated EBs at 
day 4+4 either treated with SMI1 (red) or untreated (blue). 
 
Figure 2: Characterization of skeletal muscle induction by SMI treatment 
(A) Kinetics of Pax7 luciferase activity in Pax7 luciferase knock-in ES cells after treatment with 
SMI1 or DMSO. The bars indicate standard deviation for 3 independent EBs from a 
representative experiment.  
(B) The relative transcript levels at day 4+4 of MyoD, Myf5 and Myogenin were determined by 
real-time RT-PCR analysis and plotted as fold change of untreated controls after being 
normalized to GAPDH. Both compounds were added at 10 µM at day 1 and day 4. The bars 
indicate standard deviation for 3 independent pools of 10 EBs from a representative experiment. 
(C) Immunofluorescence staining for Myogenin (red) of a mouse EB at day 4+8 (upper panel, 
scale bar indicates 20 µm) and at day 4+20 for MHC (lower panel, scale bar indicates 160 µm). 
DAPI was used to stain the nucleus. The white square indicates the region with higher 
magnification demonstrating the striation of the muscle cells. 
(D) Immunofluorescence staining for MHC (red) of a whole single EB in a 24 well plate at day 
4+20 either untreated or SMI2 treated. The image is a composition of many individual pictures in 
order to visualize the entire EB. DAPI was used to stain the nucleus. Scale bar indicates 2mm.  
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Figure 3: The Wnt pathway is critical for SMI action for skeletal muscle formation.  
(A) Microarray analysis of SMI1 treated mouse EBs revealed that Wnt pathway downstream 
genes are mostly upregulated (p<0.05). 
(B) The relative transcript levels of mesodermal markers (T and Mesogenin1) and Wnt pathway 
downstream genes (T, Mesogenin1, Axin2) in SMI2 treated EBs compared to untreated controls. 
Data is  normalized to GAPDH. RNA was isolated at day 3 and 4 after treatment with SMI2 
(10µM) at day 1. The bars indicate standard error of the mean for at least 3 independent pools of 
10 EBs from a representative experiment. (* ; p < 0.05 and *** ; p < 0.001 by student’s t test, 
significance vs control) 
(C) Relative transcript levels at day 4+4 of Pax3, Pax7, MyoD, Myf5 and Myogenin were 
determined by real-time RT-PCR analysis and plotted as fold variance of controls after being 
normalized to GAPDH. All compounds were added at 10µM at day 1 and day 4. The bars 
indicate standard error of the mean for 3 independent pools of 10 EBs from a representative 
experiment. (* ; p < 0.05 and ** ; p < 0.01 by student’s t test, significance vs SMI2 treated) 
(D) Pax7 luciferase activity of a Pax7 luciferase knock-in ES cell line after treatment at day 1 
and day 4 with SMI2 (10µM) and/or IWP3 (10µM). The bars indicate standard error of the mean 
for 4 independent EBs from a representative experiment. (** ; p < 0.01 by student’s t test) 
 
Figure 4: Inhibition of Smad2/3 signaling pathway is a key event in SMI action toward 
skeletal muscle differentiation. 
(A) Microarray analysis of mouse EBs at day4 shows that Nodal pathway related genes are 
differentially regulated at day 4 in presence of SMI1. (p<0.05)  
(B) The relative transcript levels at day 4 of FoxaA2, Gsc and Otx2 were determined by real-
time RT-PCR analysis and plotted as fold variance of SMI treated EBs to controls after being 
normalized to GAPDH. SMI1 was added at 10uM at day 1. The bars indicate standard error of 
the mean for 3 independent pools of 10 EBs from a representative experiment. (* ; p < 0.05, (** ; 
p < 0.01 and *** ; p < 0.001 by student’s t test, significance vs control) 
(C) Western blot for p-SMAD2 and p-SMAD3 indicates decreased phosphorylation on Smad2/3 
proteins in EBs which were treated at day 1 with 10µM SMI1 or 10µM SB431542, respectively. 
Protein was isolated at day4.  
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(D) The relative transcript levels at day 4+4 of Myogenin was determined by real-time RT-PCR 
analysis and plotted as fold variance of DMSO treated controls after being normalized to 
GAPDH. SMI1 was added at 10µM at day 1 and day 4. At the same time points Activin A was 
added at concentration of 50ng/ml. The bars indicate standard error of the mean for 5 
independent EBs from a representative experiment. (* ; p < 0.05 by student’s t test) 
 
 
Figure 5: Sonic Hedgehog pathway signaling is inhibited by SMI. 
(A) Microarray analysis of mouse EBs at day 4+4 in presence of SMI1 revealed that some of 
Sonic Hedgehog pathway related genes were downregulated. (p<0.05) 
(B) The relative transcript levels at day 4+4 of Shh, Gli1, and Ptch1 were determined by real-
time RT-PCR analysis and plotted as fold variance of untreated controls after being normalized 
to GAPDH. SMI2 was added at 10µM at day 1 and day 4. The bars indicate standard error of the 
mean for 3 independent pools of 10 EBs from a representative experiment. (* ; p < 0.05 by 
student’s t test, significance vs control) 
(C) Relative transcript levels at day 4+4 of Pax3, Pax7, MyoD, Myf5 and Myogenin were 
determined by real-time RT-PCR analysis and plotted as fold variance of untreated controls after 
being normalized to GAPDH. SMI2 was added at 10µM at day 1 and day 4. The Smo Agonist 
Hh-Ag1.5 was added from day 4 until day 4+4 at a concentration of 1µM. The bars indicate 
standard error of the mean for 3 independent pools of 10 EBs from a representative experiment. 
(* ; p < 0.05 and ** ; p < 0.01 by student’s t test, significance vs SMI2 treated) 
 (D) Pax7 luciferase activity of a Pax7 luciferase knock-in ES cell line at day 4+8 in mouse EB 
treated with 10µM SMI2 (day1 and day4) and 1µM Smo Agonist Hh-Ag1.5 (from day4 until day 
8). The bars indicate standard error of the mean for 4 independent EBs from a representative 
experiment. (** ; p < 0.01 by student’s t test) 
 
Figure 6: A Cocktail of small molecules can mimic the action of SMI.  
(A), (B) Graphs represent Pax7 luciferase activity in a Pax7 luciferase knock-in ES cell line at 
day 4+8 in mouse EBs treated with the indicated combination of small molecules. The 
concentration used were for NVP-LDE225 (10µM), SB431542 (2.5µM) and BIO (0.5µM). In (A) 
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LDE 225 was added at day 4 and time point of SB addition was varied and the bars indicate 
standard error of the mean for 3 independent EBs from a representative experiment. In (B), 
addition of SB431542 +NVP-LDE225 was kept constant at day 4 and the time point of addition 
of BIO was varied. The bars indicate standard error of the mean for 3 independent experiments. 
(* ; p < 0.05, ** ; p < 0.01 and *** ; p < 0.001 by ANOVA test, significance vs control) 
(C), (D) Relative transcript levels at day 4+4 (C) and day 4+8 (D) of Pax3, Pax7, MyoD, Myf5 
and Myogenin were determined by real-time RT-PCR analysis and plotted as fold variance of 
DMSO treated controls after being normalized to GAPDH. EB were treated with the 
combination of small molecules, BIO, SB431542 and NVP-LDE225 at day 4. SB431542 was 
incubated for 2 days and BIO and NVP-LDE225 were kept until day 4+6. The bars indicate 
standard error of the mean for 3 independent pools of 10 EBs from a representative experiment. 
(* ; p < 0.05, ** ; p < 0.01 and *** ; p < 0.001 by student’s t test, significance vs DMSO treated) 
(E) Immunofluorescence staining staining of Myogenin (red) and MHC (red) in mouse EB with 
combination of BIO, SB431542 and NVP-LDE225 at EB day 4+8. DAPI was used to stain the 
nucleus. Scale bar indicates 20µm. 
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Supporting Information: 
Supplementary Figure 1: Kinetic change in EB size in a 96 well ULA plate after plating of 500 
ES cells in DM medium. Each well was measured automatically with a Cellavista instrument and 
the area was calculated automatically. 
 
Supplementary Figure2: Kinetics of myogenic factor expression after addition of SMI1. The 
relative transcript levels of Pax3, Pax7, MyoD, Myf5 and Myogenin were determined by real-
time RT-PCR analysis and plotted as fold variance of DMSO treated controls at day 4 after being 
normalized to GAPDH. SMI1 was added at 10µM at day 1 and day 4.   
 
Supplementary Figure 3: SMI1 as well as BSL induced adipocyte as well as skeletal muscle 
differentation.  
(A) Bright-field microscopy images showing adipocytes on top of skeletal muscle fibres. On the 
left a culture stimulated with 10µM SMI1 and on the right in higher magnifaction a BSL 
stimulated culture.  
(B) Adipocytes were stained with Sudan Red.  
 
Supplementary Figure 4: Microarray analysis of expression levels of pluripotency genes in 
mouse ES cells and EBs treated with SMI1 at 10µM. 
 
Supplementary Figure 5:  
(A) Relative transcript levels at day 4+4 of Nkx2-5 was determined by real-time RT-PCR 
analysis and plotted as fold variance of DMSO treated controls after being normalized to 
GAPDH. SMI2 was added at 10µM at day 1 and day 4. 10µM IWP3 was added at day1.  
(B) Pax7 luciferase activity in a Pax7 luciferase knock-in ES cell line after treatment with 10µM 
SMI at day1 and day 4 or with 0.5 µM BIO at indicated time point. The bars indicate standard 
deviation. (* ; p < 0.01 by student’s t test)   
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Supplementary Figure 6:  
When mesoderm formation was inhibited by 10µM SB431542 treatment, induction of skeletal 
muscle by SMI was also inhibited. Graph shows relative transcript levels at day 4 (BraT), d4+4 
(Pax3) and d4+8 (Myogenin). Values were determined by real-time RT-PCR analysis and plotted 
as fold variance of untreated controls after being normalized to GAPDH.  
 
Supplementary Figure 7: IHC for MHC of a whole single EB in a 24 well plate at day 4+20. 
Each image is a composition of many individual pictures. Scale bar indicates 2mm. Upper row 
EBs are DMSO treated control, middle row EB treated with 10µM SMI 1 and lower row EB’ 
stimulated with BSL. 
 
Supplementary Figure 8: Graph shows relative transcript levels of Pax7, Myf5, MyoD and 
MyoG at day 4+8. SMI2 did not enhance the induction of myogenic genes mRNA level in 
combination with BSL. Values were determined by real-time RT-PCR analysis and plotted as 
fold variance of DMSO treated controls after being normalized to GAPDH. Error bars indicate 
the standard deviations. 
 
Supplementary Table 1: Applied Biosystems TaqMan Gene Expression Assays used in Real-
Time RT-PCR analysis 
Supplementary Table 2: Differentially expressed genes at day 4 and day4+4  
Supplementary Table 3: GSEA at EB day4 and day4+4 
Supplementary Table 4: Wnt signaling genes 
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MM_Supplementary Table1. GSEA at EB day4 Applied Biosystems TaqMan Gene Expression 
 Assays used in Real-Time RT-PCR analysis 
Applied Biosystems Assay ID Gene Symbol Gene Name 
4352339E GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Mm00435493_m1  Pax3 Paired box gene 3 
Mm00834079_m1 Pax7 Paired box gene 7 
Mm0440387_m1 MyoD MyoD1 
 Mm00435125_m1 Myf5 Myogenic factor 5 
Mm00446194_m1 MyoG Myogenin 
Mm01318252_m1 BrachyuryT BrachyuryT 
Mm00490407_s1 Msgn1 Mesogenin1 
Mm00443610_m1  Axin2 Axin2 
Mm01976556_s1 FoxA2 Forkhead box A2 
Mm00650681_g1 Gsc Goosecoid homeobox 
Mm00446859_m1 Otx2 Orthodenticle homolog 2 
Mm00436528_m1 Shh Sonic hedgehog 
Mm00494654_m1 Gli1 GLI Family Zinc Finger 1 
Mm00436026_m1 Ptch1 Patched 1  
Mm00657783_m1 Nkx2-5 NK2 homeobox 5 
 
  
71 
 
MM_Supplementary Table2. Differentially expressed genes at day 4 and 
day4+4 
Time point Entrez Gene Gene Symbol 
Fold Change  
SMI1 vs 
control 
day 4 101401 Adamts9 -9.26 
day 4 12622 Cer1 -6.62 
day 4 58208 Bcl11b -6.50 
day 4 66198 Them5 -5.85 
day 4 15376 Foxa2 -5.21 
day 4 14836 Gsc -4.98 
day 4 237010 Klhl4 -4.91 
day 4 13813 Eomes -4.90 
day 4 101401 Adamts9 -4.85 
day 4 58208 Bcl11b -4.57 
day 4 13813 Eomes -4.45 
day 4 17863 Myb -4.41 
day 4 101401 Adamts9 -4.30 
day 4 17863 Myb -4.30 
day 4 234267 Gpm6a 4.06 
day 4 27226 Pla2g7 4.08 
day 4 12491 Cd36 4.08 
day 4 77569 Limch1 4.09 
day 4 12491 Cd36 4.10 
day 4 14472 Gbx2 4.11 
day 4 14468 Gbp1 4.20 
day 4 237979 Sdk2 4.21 
day 4 15394 Hoxa1 4.21 
day 4 243931 Tshz3 4.21 
day 4 23962 Oasl2 4.24 
day 4 108797 Mex3b 4.27 
day 4 12591 Cdx2 4.31 
day 4 19224 Ptgs1 4.36 
day 4 353310 Zfp703 4.43 
day 4 94222 Olig3 4.44 
day 4 14654 Glra1 4.53 
day 4 100038882 /// 677168 Gm9706 /// Isg15 4.65 
day 4 14469 Gbp2 4.66 
day 4 15438 Hoxd9 4.66 
day 4 15410 Hoxb3 4.68 
day 4 100039796 /// 21822 Tgtp /// Tgtp2 4.71 
day 4 20231 Nkx1-2 4.74 
day 4 14469 Gbp2 4.76 
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day 4 15402 Hoxa5 4.77 
day 4 13838 Epha4 4.85 
day 4 13838 Epha4 5.14 
day 4 229900 Gbp6 5.19 
day 4 20274 Scn9a 5.24 
day 4 55932 Gbp3 5.29 
day 4 244867 Arhgap20 5.38 
day 4 100038499 Gm10672 5.44 
day 4 12903 Crabp1 5.57 
day 4 54140 Avpr1a 5.59 
day 4 381290 Atp2b4 5.75 
day 4 208076 Pknox2 6.04 
day 4 20682 Sox9 6.07 
day 4 20128 Trim30 6.18 
day 4 20274 Scn9a 6.20 
day 4 15410 Hoxb3 6.21 
day 4 11846 Arg1 6.24 
day 4 15407 Hoxb1 6.73 
day 4 15400 Hoxa3 6.73 
day 4 218820 Zfp503 6.80 
day 4 103889 Hoxb2 6.90 
day 4 66640 5730446D14Rik 7.07 
day 4 12591 Cdx2 7.25 
day 4 68169 A930038C07Rik 7.96 
day 4 15957 Ifit1 8.06 
day 4 67775 Rtp4 9.16 
day 4 16392 Isl1 9.19 
day 4 15399 Hoxa2 9.63 
day 4 100048346 /// 24110 LOC100048346 /// Usp18 9.71 
day 4 20755 Sprr2a 10.83 
day 4 20755 Sprr2a 11.51 
day 4 15400 Hoxa3 12.36 
day 4 20664 Sox1 14.18 
 
Time point Entrez Gene Gene Symbol 
Fold Change  
SMI1 vs 
control 
day 4+4 17906 Myl2 -25.30 
day 4+4 56720 Tdo2 -22.91 
day 4+4 17897 Myl3 -19.49 
day 4+4 71693 Colec11 -18.67 
day 4+4 22139 Ttr -17.51 
73 
 
day 4+4 22139 Ttr -13.51 
day 4+4 22139 Ttr -13.50 
day 4+4 17897 Myl3 -13.29 
day 4+4 15375 Foxa1 -12.72 
day 4+4 22044 Trh -12.55 
day 4+4 14765 Gpr50 -12.42 
day 4+4 22139 Ttr -12.04 
day 4+4 20423 Shh -11.83 
day 4+4 20997 T -11.52 
day 4+4 17888 Myh6 -11.37 
day 4+4 15227 Foxf1a -11.12 
day 4+4 19733 Rgn -11.07 
day 4+4 12404 Cbln1 -10.90 
day 4+4 18511 Pax9 -10.58 
day 4+4 213435 Mylk3 -10.39 
day 4+4 12404 Cbln1 -10.38 
day 4+4 23937 Mab21l2 -10.04 
day 4+4 207683 Igsf11 -9.73 
day 4+4 15110 Hand1 -9.46 
day 4+4 22113 Phlda2 -9.24 
day 4+4 12627 Cfc1 -9.19 
day 4+4 15209 Hesx1 -8.81 
day 4+4 12591 Cdx2 -8.69 
day 4+4 110257 /// 15122 Hba-a1 /// Hba-a2 -8.46 
day 4+4 18424 Otx2 -8.35 
day 4+4 16521 Kcnj5 -8.32 
day 4+4 20208 Saa1 -8.20 
day 4+4 100046336 /// 268729 Gm626 /// LOC100046336 -7.81 
day 4+4 15132 Hbb-bh1 -7.81 
day 4+4 15132 Hbb-bh1 -7.66 
day 4+4 12404 Cbln1 -7.46 
day 4+4 21687 Tek -7.44 
day 4+4 68190 5330426P16Rik -7.25 
day 4+4 15110 Hand1 -7.25 
day 4+4 17022 Lum -7.19 
day 4+4 17897 Myl3 -7.19 
day 4+4 353283 Eras -7.02 
day 4+4 17898 Myl7 -6.94 
day 4+4 21387 Tbx4 -6.94 
day 4+4 76142 Ppp1r14c -6.87 
day 4+4 19662 Rbp4 -6.77 
day 4+4 14261 Fmo1 -6.74 
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day 4+4 244954 Prss35 -6.68 
day 4+4 15132 Hbb-bh1 -6.64 
day 4+4 23796 Aplnr -6.63 
day 4+4 13009 Csrp3 -6.62 
day 4+4 20730 Spink3 -6.59 
day 4+4 57246 Tbx20 -6.54 
day 4+4 12622 Cer1 -6.50 
day 4+4 225583 A730017C20Rik 6.55 
day 4+4 77630 Prdm8 6.55 
day 4+4 70911 Phyhipl 6.55 
day 4+4 72711 2810037O22Rik 6.57 
day 4+4 17927 Myod1 6.58 
day 4+4 18509 Pax7 6.59 
day 4+4 27386 Npas3 6.70 
day 4+4 271305 Phf21b 6.70 
day 4+4 100039795 Ildr2 6.73 
day 4+4 21826 Thbs2 6.74 
day 4+4 77483 C030044C12Rik 6.75 
day 4+4 100223 9630041G16Rik 6.76 
day 4+4 20614 Snap25 6.84 
day 4+4 108030 Lin7a 6.84 
day 4+4 21826 Thbs2 6.87 
day 4+4 68659 1110032E23Rik 6.89 
day 4+4 208936 Adamts18 6.92 
day 4+4 18124 Nr4a3 6.93 
day 4+4 19283 Ptprz1 7.02 
day 4+4 13388 Dll1 7.03 
day 4+4 26414 Mapk10 7.09 
day 4+4 15402 Hoxa5 7.11 
day 4+4 13175 Dclk1 7.12 
day 4+4 11468 Actg2 7.12 
day 4+4 20269 Scn3a 7.18 
day 4+4 20897 Stra6 7.20 
day 4+4 269637 Cnpy1 7.25 
day 4+4 70580 5730478J17Rik 7.26 
day 4+4 12818 Col14a1 7.30 
day 4+4 11899 Astn1 7.31 
day 4+4 109323 C1qtnf7 7.40 
day 4+4 58238 Fam181b 7.41 
day 4+4 12393 Runx2 7.44 
day 4+4 83671 Sytl2 7.46 
day 4+4 107589 Mylk 7.46 
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day 4+4 16323 Inhba 7.48 
day 4+4 16876 Lhx9 7.58 
day 4+4 69239 2610034M16Rik 7.60 
day 4+4 17313 Mgp 7.60 
day 4+4 15423 Hoxc4 7.71 
day 4+4 74002 Psd2 7.72 
day 4+4 13175 Dclk1 7.73 
day 4+4 20665 Sox10 7.79 
day 4+4 13175 Dclk1 7.80 
day 4+4 67828 Lce1f 7.81 
day 4+4 74644 4930426D05Rik 7.83 
day 4+4 18212 Ntrk2 7.97 
day 4+4 26757 Dpysl4 7.97 
day 4+4 101694 AI854517 8.02 
day 4+4 17877 Myf5 8.06 
day 4+4 21925 Tnnc2 8.06 
day 4+4 20262 Stmn3 8.21 
day 4+4 15950 Ifi203 8.26 
day 4+4 17883 Myh3 8.26 
day 4+4 16939 Lor 8.27 
day 4+4 13175 Dclk1 8.32 
day 4+4 15571 Elavl3 8.35 
day 4+4 474332 Dnm3os 8.42 
day 4+4 330096 Shisa3 8.43 
day 4+4 18039 Nefl 8.46 
day 4+4 225631 Onecut2 8.54 
day 4+4 54003 Nell2 8.55 
day 4+4 246048 Chodl 8.60 
day 4+4 21367 Cntn2 8.61 
day 4+4 18212 Ntrk2 8.62 
day 4+4 18508 Pax6 8.64 
day 4+4 18996 Pou4f1 8.74 
day 4+4 17901 Myl1 8.75 
day 4+4 23876 Fbln5 8.84 
day 4+4 67374 Jam2 8.84 
day 4+4 17756 Mtap2 8.85 
day 4+4 18012 Neurod1 8.91 
day 4+4 11609 Agtr2 8.98 
day 4+4 15248 Hic1 9.01 
day 4+4 16939 Lor 9.10 
day 4+4 78286 Nav2 9.16 
day 4+4 244867 Arhgap20 9.41 
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day 4+4 75036 4930488B01Rik 9.42 
day 4+4 17907 Mylpf 9.51 
day 4+4 56370 Tagln3 9.58 
day 4+4 75395 0610040B09Rik 9.59 
day 4+4 74694 Tbc1d30 9.63 
day 4+4 70008 Ace2 9.69 
day 4+4 12307 Calb1 9.82 
day 4+4 18992 Pou3f2 9.90 
day 4+4 16979 Lrrn1 10.00 
day 4+4 67606 Fibin 10.09 
day 4+4 58238 Fam181b 10.16 
day 4+4 12661 Chl1 10.29 
day 4+4 11438 Chrna4 11.02 
day 4+4 77994 2810055G20Rik 11.27 
day 4+4 15572 Elavl4 11.34 
day 4+4 81799 C1qtnf3 11.66 
day 4+4 100047943 LOC100047943 11.66 
day 4+4 19051 Gsbs 11.80 
day 4+4 75426 Igfbpl1 11.89 
day 4+4 15379 Onecut1 11.97 
day 4+4 110834 Chrna3 11.99 
day 4+4 246104 Rhbdl3 12.08 
day 4+4 15572 Elavl4 12.12 
day 4+4 210293 Dock10 12.20 
day 4+4 109272 Mybpc1 12.48 
day 4+4 319723 9430053O09Rik 12.53 
day 4+4 18197 Nsg2 12.53 
day 4+4 14025 Bcl11a 12.58 
day 4+4 14654 Glra1 12.71 
day 4+4 75770 Brsk2 12.80 
day 4+4 100047943 /// 226180 Ina /// LOC100047943 12.86 
day 4+4 15424 Hoxc5 12.90 
day 4+4 18214 Ddr2 12.92 
day 4+4 17200 Mc2r 13.15 
day 4+4 14025 Bcl11a 13.15 
day 4+4 226049 Dmrt2 13.32 
day 4+4 474332 Dnm3os 13.82 
day 4+4 75426 Igfbpl1 13.86 
day 4+4 18505 Pax3 14.00 
day 4+4 15572 Elavl4 14.04 
day 4+4 108030 Lin7a 14.06 
day 4+4 20604 Sst 14.13 
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day 4+4 77994 2810055G20Rik 14.20 
day 4+4 94090 Trim9 14.22 
day 4+4 14025 Bcl11a 14.23 
day 4+4 55985 Cxcl13 14.46 
day 4+4 235180 Fez1 14.73 
day 4+4 14025 Bcl11a 14.86 
day 4+4 94090 Trim9 14.94 
day 4+4 15424 Hoxc5 14.95 
day 4+4 13797 Emx2 14.99 
day 4+4 11921 Atoh1 15.03 
day 4+4 16814 Lbx1 15.09 
day 4+4 67374 Jam2 15.28 
day 4+4 545474 Scrt2 15.63 
day 4+4 15571 Elavl3 15.66 
day 4+4 21367 Cntn2 15.72 
day 4+4 268755 A930011O12Rik 15.74 
day 4+4 13837 Epha3 15.91 
day 4+4 545474 Scrt2 16.37 
day 4+4 240690 St18 16.38 
day 4+4 224419 ORF63 16.73 
day 4+4 20464 Sim1 16.90 
day 4+4 22408 Wnt1 17.18 
day 4+4 77427 9430092D12Rik 17.24 
day 4+4 68955 1500001A10Rik 17.25 
day 4+4 320521 6430547I21Rik 18.58 
day 4+4 12140 Fabp7 18.59 
day 4+4 94090 Trim9 18.83 
day 4+4 18040 Nefm 20.71 
day 4+4 76161 6330527O06Rik 20.99 
day 4+4 71137 Rfx4 21.43 
day 4+4 545474 Scrt2 21.99 
day 4+4 13176 Dcc 22.15 
day 4+4 18505 Pax3 22.36 
day 4+4 13837 Epha3 23.00 
day 4+4 15208 Hes5 23.36 
day 4+4 73100 2900092D14Rik 23.62 
day 4+4 53626 Insm1 24.09 
day 4+4 434147 D930028M14Rik 26.06 
day 4+4 13193 Dcx 26.36 
day 4+4 14560 Gdf10 26.42 
day 4+4 100041799 Gm3515 26.96 
day 4+4 21419 Tcfap2b 27.30 
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day 4+4 213262 Fstl5 27.41 
day 4+4 232714 Mgam 27.53 
day 4+4 18993 Pou3f3 27.64 
day 4+4 17928 Myog 28.92 
day 4+4 381813 Prmt8 30.57 
day 4+4 94222 Olig3 31.93 
day 4+4 13193 Dcx 34.06 
day 4+4 18509 Pax7 34.80 
day 4+4 17703 Msx3 36.18 
day 4+4 17172 Ascl1 47.44 
day 4+4 11924 Neurog2 49.74 
day 4+4 18071 Nhlh1 50.45 
day 4+4 20715 Serpina3g 51.10 
day 4+4 66297 2610017I09Rik 54.66 
day 4+4 27220 Cartpt 54.94 
day 4+4 18014 Neurog1 56.27 
day 4+4 21419 Tcfap2b 61.37 
day 4+4 100040120 Gm2612 63.34 
day 4+4 320203 C130071C03Rik 84.66 
day 4+4 11923 Neurod4 85.41 
day 4+4 17932 Myt1 88.40 
day 4+4 13176 Dcc 93.72 
day 4+4 11923 Neurod4 111.29 
day 4+4 14089 Fap 139.20 
day 4+4 22771 Zic1 144.00 
day 4+4 320203 C130071C03Rik 149.97 
day 4+4 22771 Zic1 173.37 
day 4+4 18072 Nhlh2 190.03 
 
MM_Supplementary Table3. GSEA at EB day4 and day4+4 
 Time 
Point Pathway Name Up/Down 
day 4 
Stem cells_H3K27 demethylases in differentiation of stem 
cells Up 
day 4 
Stem cells_FGF2 signaling during embryonic stem cell 
differentiation Up 
day 4 
Stem cells_Extraembryonic differentiation of embryonic 
stem cells Up 
day 4 Stem cells_Astrocyte differentiation from adult stem cells Up 
day 4 
Stem cells_Scheme: FGF signaling in embryonic stem cell 
self-renewal and differentiation Up 
day 4 Stem cells_Embryonal  epaxial myogenesis  Up 
day 4 Stem cells_H3K4 demethylases in stem cell maintenance Up 
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day 4 Stem cells_BMP7 in brown adipocyte differentiation Up 
day 4 
Stem cells_WNT/Beta-catenin and NOTCH in induction of 
osteogenesis Up 
day 4 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal 
remodeling Up 
day 4 
Stem cells_WNT and Notch signaling in early cardiac 
myogenesis Up 
day 4 
Stem cells_NOTCH in inhibition of WNT/Beta-catenin-
induced osteogenesis Up 
day 4 
Stem cells_TNF-alpha, IL-1 alpha and WNT5A-dependent 
regulation of osteogenesis and adipogenesis in 
mesenchymal stem cells Up 
day 4 Development_WNT signaling pathway. Part 2 Up 
day 4 Development_WNT5A signaling Up 
day 4 
Stem cells_NODAL signaling in early mesendoderm 
formation Down 
day 4 
Stem cells_FGF and BMP signaling in early embryonic 
hepatogenesis Down 
day 4 Stem cells_Histone acetylation in embryonic stem cells Down 
day 4 
Stem cells_Inhibition of Hedgehog signaling in 
medulloblastoma stem cells Down 
day 4 Stem cells_Trophectoderm differentiation Down 
day 4 
Stem cells_Role of BMP signaling in embryonic stem cell 
neural differentiation Down 
day 4 
Stem cells_Signaling pathways in embryonic hepatocyte 
maturation Down 
day 4 
Stem cells_FGF signaling in pancreatic and hepatic 
differentiation of embryonic stem cells Down 
day 4 
Stem cells_Scheme: FGF signaling in embryonic stem cell 
self-renewal and differentiation Down 
day 4 
Stem cells_TGF-beta family mediated differentiation of 
embryonic stem cells Down 
day 
4+4 
Stem cells_FGF2 signaling during embryonic stem cell 
differentiation Up 
day 
4+4 Stem cells_H3K4 demethylases in stem cell maintenance Up 
day 
4+4 Stem cells_Early embryonal hypaxial myogenesis Up 
day 
4+4 Stem cells_H3K36 demethylation in stem cell maintenance Up 
day 
4+4 Stem cells_Astrocyte differentiation from adult stem cells Up 
day 
4+4 Stem cells_BMP7 in brown adipocyte differentiation Up 
day 
4+4 
Development_WNT signaling pathway. Part 1. Degradation 
of beta-catenin in the absence WNT signaling Up 
day 
4+4 Stem cells_Embryonal  epaxial myogenesis  Up 
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day 
4+4 Signal transduction_Activin A signaling regulation Down 
day 
4+4 
Stem cells_NODAL signaling in early mesendoderm 
formation Down 
day 
4+4 
Stem cells_Inhibition of Hedgehog signaling in 
medulloblastoma stem cells Down 
day 
4+4 Stem cells_Trophectoderm differentiation Down 
day 
4+4 Development_VEGF-family signaling Down 
day 
4+4 
Development_Hedgehog and PTH signaling pathways in 
bone and cartilage development Down 
day 
4+4 Stem cells_BMP signaling in cardiac myogenesis Down 
day 
4+4 
Stem cells_Scheme: FGF signaling in embryonic stem cell 
self-renewal and differentiation Down 
day 
4+4 
Stem cells_Cooperation between Hedgehog, IGF-2 and 
HGF signaling pathways in medulloblastoma stem cells Down 
 
MM_Supplementary Table4. Wnt signaling genes 
Entrez Gene Gene Symbol Fold Change  SMI1 vs control 
73173 Pcdh18 3.52 
22418 Wnt5a 3.05 
93897 Fzd10 2.90 
15401 Hoxa4 2.72 
15402 Hoxa5 2.61 
15413 Hoxb5 2.47 
12444 Ccnd2 2.41 
15412 Hoxb4 2.35 
22420 Wnt6 2.03 
170677 Pcdh21 -2.31 
12552 Cdh11 -2.88 
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Chapter 3: Additional result 
 
In this chapter I present the data of microRNA and mRNA expression levels from differentiated 
EBs with and without SMI1 treatment. These data were not included in the submitted manuscript. 
However, the data set below could give uncovered information about SMI1 and SMI2 which I 
did not address in the submitted manuscript.  
 
3.1.  MicroRNA Microarray during embryonic skeletal muscle 
differentiation by SMI1 
 
3.1.1. Background 
MicroRNAs (miRNAs) are small noncoding RNAs which are 19 to 25 nucleotides in size (Kim, 
2005). They are transcribed in the nucleus, processed by the RNases Drocha/DGCR8 and Dicer 
(Reviewed in He and Hannon, 2004). And they are involved in controlling gene expression at 
post-transcriptional level by binding to complementary target mRNAs. The interaction between 
miRNA and mRNA in RNA induced silencing complexes results in mRNA degradation, 
deadenylation or translational repression at the level of the ribosome (Reviewed in He and 
Hannon, 2004). miRNAs have appeared as important players in controlling stem cell fate and 
behavior. Indeed overexpression of muscle specific microRNA, miR-1, in mouse embryonic 
stem cells could guide the differentiation of cells to mesoderm by suppressing differentiation to 
endoderm and neuroectoderm lineage (Ivey et al., 2008). Potential target of miR-1 in this system 
was Dll-1 which was known to promote neural differentiation and inhibit muscle differentiation 
in ES cells previously (Lowell et al., 2006; Nemir et al., 2006). 
There are also embryonic stem cell specific miRNAs which are abundant in ES cells and keep 
the characteristics of pluripotency and self-renewal (Houbaviy et al., 2003; Melton et al., 2010). 
Most of them are encoded by the miR-290 cluster. Some of them are sharing the hexamer seed 
‘AAGUGC’ including miR-290-3p, miR-291a-3p, miR-291b-3p, miR-292-3p, miR-294, miR-
295. The other members of this cluster are miR-290-5p, miR-291a-5p, miR-292-5p, miR-293, 
82 
 
miR-293*, miR-294* and miR-295*. The miR-290 cluster is located on chromosome 7 on a 
DNA fragment of 2.2kb (Marson et al., 2008). Interestingly ES cells specific miRNAs like miR-
291-3p, miR-294 and miR-295, which regulate cell cycle, promoted the process of induced 
pluripotent stem cell generation when added to the three known reprogramming factors, OSK 
(Oct4, Sox2 and Klf4) (Judson et al., 2009). MiR-302 family is also expressed in ES cells (Suh et 
al., 2004). MiR-302b plays a role in maintenance of stemness of human embryonal carcinoma 
(Lee et al., 2008). Overexpression of miR-302 leads to reprogramming of human hair follicle 
cells to induced pluripotent stem cells (Lin et al., 2011). The ES cell specific miRNAs control 
the unique cell cycle program of ES cells characterized by a short G1 phase and a high 
proportion of cells in S-phase (White and Dalton, 2005). They target the inhibitors of the G1 and 
S phase transition such as p21 and Rb2 (Subramanyam et al., 2011).  
Besides ES cell specific miRNAs, muscle specific miRNAs also have been described. MiR-1, 
miR-133a and miR-206 are known as muscle specific miRNAs (Kim et al., 2006). Unlike miR-1 
and miR-133a that express both in heart and skeletal muscle, miR-206 is expressed only in 
skeletal muscle. Skeletal muscle specific miR-206 promoted the differentiation in skeletal 
myoblasts by regulating many genes. For example it is reported that miR-206 targets Pax7 3’-
UTR (Chen et al., 2010). By repressing Pax7, miR-206 regulates skeletal muscle satellite cell 
proliferation and its differentiation to myotubes. 
The reports above indicate that miRNA can control the cell fate. Based on the previous findings, 
I asked if 1) SMI treatment is specifically inducing key miRNAs during differentiation and 2) it 
is possible to drive the differentiation to skeletal muscle ultimately by modifying the level of 
miRNAs. With the similar approach to the study of Ivey et al, I wanted to test either ectopic 
overexpression or inhibition of specific miRNAs during mouse ES cells differentiation.  
We performed a TaqMan based miRNA Microarray with the RNA samples from EB 
differentiated to day 4 and day 4+4 with or without SMI1 compound using the kit named 
Megaplex Primer Pools and TaqMan MicroRNA from Applied Biosystems. This method was 
based on TaqMan analysis in the 384-well fluidic card. U6 small RNA was used for 
normalization of level of each miRNA. The cards were designed to detect for 591 miRNAs in 
total, including mouse and rat miRNAs.   
83 
 
 
3.1.2. miRNAs changes at EB day 4 
Table 3.1: Differentially regulated miRNAs by SMI1 at EB day 4 
microRNA ID 
-Part Number 
Fold Change 
 EBs at d4  
Unt VS. SMI1 
p-value  
EBs at d4  
Unt VS. SMI1 
Reference 
mmu-miR-133a 
-4395357 -8.206 9.67E-03 
Specifically expressed in muscles 
(Yu et al., 2014a) 
mmu-miR-193* 
-4395707 -6.941 7.17E-03 
Suppress the metastasis  
of human lung cancer  
(Yu et al., 2014b) 
mmu-miR-741 
-4395587 -3.859 1.78E-02  
mmu-miR-302b* 
-4381043 -3.823 3.40E-02 
Highly expressed in ES cells  
(Suh et al., 2004) 
mmu-miR-302c* 
-4395687 -2.991 6.28E-03 
Highly expressed in ES cells  
(Suh et al., 2004) 
mmu-miR-339-3p 
-4395663 -2.858 3.36E-02  
mmu-miR-292-5p 
-4373324 -2.480 4.06E-02 
Highly expressed in ES cells  
(Zheng et al., 2011) 
    
mmu-miR-143 
-4395360 21.499 7.61E-06 
Control the proliferation  
of smooth muscle  
(Cordes et al., 2009) 
mmu-miR-491 
-4381053 20.661 2.72E-02 
Induce apoptosis  
in colorectal cancer cells  
(Nakano et al., 2010) 
mmu-miR-196b 
-4395326 13.900 6.50E-03 
Regulate translation of mouse insulin2 
(Panda et al., 2014) 
mmu-miR-377 
-4373025 9.791 3.43E-02 
Inhibit proliferation of human 
glioblastoma cells 
(Zhang et al., 2014) 
mmu-miR-154 
-4373270 9.769 9.64E-03 
Inhibit prostate cancer cell proliferation 
(Zhu et al., 2014) 
mmu-miR-674 
-4395193 6.779 5.10E-05  
mmu-miR-375 
-4373027 6.494 3.01E-02 
Regulate insulin secretion 
(Poy et al., 2004) 
mmu-miR-132 
-4373143 5.942 1.46E-06 
Suppress migration  
of lung cancer cells 
(You et al., 2014) 
mmu-miR-467e 
-4395698 5.347 1.97E-02  
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mmu-miR-181c 
-4373115 2.986 2.39E-02 
Regulate myeloid differentiation and 
acute myeloid leukemia 
(Su et al., 2014) 
mmu-miR-500 
-4395736 2.791 6.18E-03 
Potential diagnostic marker for 
hepatocellular carcinoma 
(Yamamoto et al., 2009) 
mmu-miR-590-5p 
-4395176 2.708 2.70E-02 
Inhibition of human cardiosphere-
derived stem cells differentiation  
(Tousi et al., 2014) 
mmu-miR-351 
-4373345 2.527 3.01E-02 
Promote muscle progenitor cell 
proliferation 
(Chen et al., 2012) 
mmu-miR-135b 
-4395372 2.405 1.10E-02 
Promote cancer progression  
in colon cancer 
(Valeri et al., 2014) 
mmu-miR-652 
-4395463 2.087 1.41E-02 
Control heart function and hypertrophy 
(Bernardo et al., 2014) 
rno-miR-351 
-4395764 2.012 2.44E-03 
Promote muscle progenitor  
cell proliferation 
(Chen et al., 2012) 
 
At day 4 of EB formation, 3 days after SMI1 treatment, 7 miRNAs were decreased and 16 
miRNAs were increased more than 2 fold with a p-value of 0.05 (Table 3.1). Although there 
were few miRNAs that were changed, one of the pronounced differences in SMI1 treated EBs 
compared to negative control group was the ES cell specific expressed miRNAs’ level. MiR-
302b*, miR-302c* and miR-292-5p were significantly down-regulated by SMI1. The SMI1 
treated EBs seemed more differentiated already at day4 compared to the negative control group. 
Muscle specific miRNA-133a was the most downregulated one by SMI1 incubation. MiR-133a 
is expressed in both heart and skeletal muscle (Kim et al., 2006). Decreased miR-133a can be 
because of inhibition of cardiac muscle differentiation by SMI1. In the control group without 
SMI1 incubation, beating cardiomyocytes appear but not in EB with SMI1. Compared to the 
control group, reduced differentiation to cardiac muscle lineage could be reflected as decreased 
level of miR-133a.  
MiR-143 has been repeatedly reported to be downregulated in human colorectal adenocarcinoma 
together with miR-145 (Michael et al., 2003). In other study miR-143 was reported as the most 
enriched miRNA during differentiation of mouse ES cells into multipotent cardiac progenitors 
before localized to smooth muscle cells and vascular smooth muscle cells (Ivey et al., 2008). In 
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our study, the level of miR-143 was also peaked at EB day4 with SMI1 treatment. Continued 
study of the other group revealed that miR-143 and miR-145 regulates the proliferation of 
smooth muscle cells via modulating the complex of SRF (serum response factor) (Cordes et al., 
2009).  
MiR-375 was expressed about 6 times more in EB treated by SMI1. Knockdown of miR-375 
using morpholino oligonucleotides in zebrafish demonstrated that miR-375 is essential for 
embryonic development and function of endocrine pancreas (Kloosterman et al., 2007). 
Inhibition of miR-375 causes defects in the morphology of the pancreatic islet. The known target 
of miR-375 is myotropin, one of the regulators in insulin secretion (Poy et al., 2004). 
Interestingly, overexpression of miR-375 in human ES cells showed the pancreatic islet 
differentiation expressing endodermal and endocrine-specific markers such as HNF4alpha, Pdx1, 
Pax6 and releasing insulin upon glucose stimulation (Lahmy et al., 2013).  
MiR-351 was expressed around 2.5 times more in SMI1 treated EB group. The level of miR-351 
was increased transiently in muscle regeneration model by CTX injection. It promotes skeletal 
muscle progenitor cell proliferation and survival upon differentiation (Chen et al., 2012). 
Inhibition of miR-351 in muscle progenitor cell differentiation showed more apoptosis. And 
overexpression of miR-351 did the opposite action suggesting miR-351 inhibits apoptosis. 
However the effect of miR-351 in EB differentiation was not revealed yet. 
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3.1.3. Increased miRNAs at EB day 4+4 
Table 3.2: Top 20 increased miRNAs by SMI1 at EB day 4+4 
microRNA ID 
-Part Number 
Fold Change 
 EBs at d4+4  
Unt VS. Cpd1 
p-value  
EBs at d4+4  
Unt VS. Cpd1 
Reference 
rno-miR-219-3p 
-4395501 688.875 5.64E-16 
Tumor suppressor in gastric 
cancer 
(Lei et al., 2013) 
mmu-miR-219-5p 
-4373080 372.828 7.39E-06 
Regulate neural precursor 
differentiation 
(Hudish et al., 2013) 
mmu-miR-206 
-4373092 306.243 6.79E-07 
Specifically expressed in 
skeletal muscles 
(McCarthy, 2008) 
mmu-miR-615-5p 
-4395464 283.479 2.20E-07  
mmu-miR-124 
-4373295 231.537 7.24E-05 
Control neural differentiation 
(Neo et al., 2014) 
mmu-miR-9 
-4373285 160.056 3.71E-08 
Control neural differentiation 
(Krichevsky et al., 2006) 
mmu-miR-137 
-4373301 136.510 1.32E-14 
Tumor suppressor in 
neuroblastoma 
(Althoff et al., 2013) 
mmu-miR-216b 
-4395437 94.683 9.53E-05 
Biomarker for acute pancreatic 
injury 
(Endo et al., 2013) 
mmu-let-7b 
-4373168 93.918 1.20E-04  
mmu-miR-125b* 
-4395638 80.061 7.67E-08  
mmu-miR-217 
-4395686 80.035 3.14E-10  
mmu-miR-9* 
-4395342 75.807 6.28E-08  
mmu-miR-486 
-4378096 32.938 3.08E-04 
Skeletal muscle enriched 
microRNA 
(Small et al., 2010) 
mmu-let-7c 
-4373167 31.459 3.97E-07  
rno-miR-99a* 
-4395774 30.510 2.06E-04  
mmu-miR-383 
-4381093 26.981 5.52E-04 
Regulate testicular embryonal 
carcinoma cell proliferation 
(Lian et al., 2010) 
mmu-miR-214 
-4395417 24.279 1.94E-04 
Regulate skeletal myoblast 
differentiation 
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(Juan et al., 2009) 
mmu-miR-99a 
-4373008 23.563 2.12E-03  
mmu-let-7f 
-4373164 23.287 2.37E-04  
mmu-miR-199a-5p 
-4373272 23.062 2.13E-02 
Affect Wnt signaling and 
myogenic differentiation in 
dystrophic muscle 
(Alexander et al., 2013) 
 
In comparison with the time point at day 4, more miRNAs were differentially expressed at EB 
day 4+4. 50 miRNAs in total were increased by SMI1 at day 4+4. As expected, the skeletal 
muscle specific miRNA miR-206, was upregulated in SMI1 treated EB. Interestingly expression 
pattern of miRNAs suggests that SMI1 drives EBs into not only skeletal muscle but also the 
neuronal lineages. Some neuron specific miRNAs were also highly induced by SMI. 
MiR-124a and miR-9 which are annotated as brain specific microRNAs were dramatically up-
regulated by SMI1. This upregulation was also found in ES cell derived neurogenesis in vitro 
(Krichevsky et al., 2006). The function of miR-124a and miR-9 was tested during neuron 
differentiation by overexpression. They carried out a quantitative analysis to determine the 
proportion of neuronal and astroglial-like cell populations. Transient overexpression of miR-
124a and miR-9 in neural precursors resulted in reduction of GFAP positive cells (astrocytes) 
and slight increase on the number of Tuj1 positive cells (neurons). As a result the ratio between 
GFAP positive cells and Tuj1 positive cells was shifted in more Tuj1 positive cells. It shows that 
these miRNAs play a functional role in the determination of neural fates during ES cell 
differentiation. 
MiR-214 was also significantly upregulated by SMI1 treatment. Previously it was reported that 
miR-214 targets the polycomb protein Ezh2 by binding to 3’-UTR of Ezh2 (Juan et al., 2009). In 
the study, miR-214 transduction in myoblasts reduced the level of Ezh2 and initiated premature 
expressions of myogenin and myosin heavy chain. It resulted in higher percentage of MHC 
positive cells. In ES cells overexpression of miR-214 did repress the pluripotent marker Oct4 and 
influence many developmental regulators for example increased Nestin, Dkk1, Sox17 and Pax7. 
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But it did not activate the transcription of MyoD. It suggests that miR-214 controls the 
differentiation at distinct developmental steps by regulating Ezh2 protein levels. 
Based on the observation that skeletal muscle specific miR-206 was upregulated by SMI1, I 
tested overexpression of miR-206 during EB differentiation. The pre-miR-206 was amplified 
from genomic DNA. The level of miR-206 was induced over 120 times in comparison with 
control group. However, there was no dramatic increase on Myogenin which is a marker for 
skeletal muscle. At EB day4+8, there was a tendency of increased Myogenin and decreased Pax6 
and Myh6, marker for neuronal and cardiomyocyte lineage, respectively. Overexpression of 
miR-206 was not sufficient to push drive EB differentiation to skeletal muscle.  
For further study, modification of multiple miRNAs, for example decreased embryonic stem cell 
specific miRNAs and increased skeletal muscle specific miRNA at the same time could improve 
the direct differentiation process to skeletal muscle from ES cells. 
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(A) miR-206 level in EB at day 4+8 
 
(B) Level of lineage markers in EB at day 4+8 
 
Figure 3.1: RNA levels in EB (A) Level of miR-206 measured by real-time RT-qPCR. 
(B) mRNA levels measured by real-time RT-PCR. Bars indicate the standard deviation 
in 2 samples from 10 EBs. 
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3.1.4. Decreased miRNAs at EB day 4+4 
38 miRNAs were downregulated significantly at EB day 4+4 in total. ES cell specific miRNAs 
were still downregulated at day 4+4. Compared to day 4, more ES cell specific miRNAs’ were 
reduced, including miR-290-3p, -5p, miR-291a-3p, 291b-5p and miR-302 family. Interestingly, 
expression of miR-1, one of the muscle specific miRNAs, was reduced in SMI1 treated group. 
MiR-1 expression was found in both cardiac and skeletal muscle. It is probable that decreased 
cardiac muscle differentiation in SMI1 treated group could be reflected to the decreased level of 
miR-1.  
MiR-483*, known as miR-483-3p, was significantly down-regulated. In adipocyte differentiation 
system, knocking down of this miRNA leads to more differentiation of adipose tissues (Ferland-
McCollough et al., 2012). Indeed SMI treatment not only results in skeletal muscle but also in 
adipocyte formation. The decrease of miR-483-3p might support this observation.  
By taking advantage of bioinformatics tools, further analysis can give potential key microRNAs 
which can program the differentiation of EBs to skeletal muscle. For example, target prediction 
algorithm expected that six miRNAs, miR-182, miR-186, miR-135, miR-491, miR-329 and miR-
96 had the seed sequence to bind the myogenin 3’-UTR (Antoniou et al., 2014). The potential 
miRNAs which target myogenic regulatory factors should be decreased. At the same time, 
miRNAs which target proteins enhancing differentiation of other cell lineages should be 
upregulated. 
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Table 3.3: Top 20 decreased miRNAs by SMI1 at EB day 4+4  
microRNA ID 
-Part Number 
Fold Change 
 EBs at d4+4  
Unt VS. Cpd1 
p-value  
EBs at d4+4  
Unt VS. Cpd1 
Reference 
mmu-miR-291b-5p 
-4395667 -81.119 4.36E-06 
Highly expressed in ES cells  
(Zheng et al., 2011) 
mmu-miR-302c* 
-4395687 -48.969 6.17E-08 
Highly expressed in ES cells  
(Suh et al., 2004) 
mmu-miR-294* 
-4395725 -44.742 2.86E-04 
Highly expressed in ES cells  
(Zheng et al., 2011) 
mmu-miR-302c 
-4395688 -41.016 2.87E-07 
Highly expressed in ES cells  
(Suh et al., 2004) 
mmu-miR-297c 
-4395610 -35.533 1.69E-06 
Modulate multidrug resistance 
in human colorectal carcinoma 
(Xu et al., 2012) 
mmu-miR-302a* 
-4395745 -27.018 1.38E-04 
Highly expressed in ES cells  
(Suh et al., 2004) 
mmu-miR-367 
-4373034 -26.751 3.50E-08 
Highly expressed in ES cells  
(Suh et al., 2004) 
mmu-miR-96 
-4373372 -23.760 8.49E-03 
Repress neural induction in 
human ES cells 
(Du et al., 2013) 
mmu-miR-302b 
-4378071 -20.249 1.13E-07 
Highly expressed in ES cells  
(Suh et al., 2004) 
mmu-miR-302a 
-4378070 -18.547 7.13E-04 
Highly expressed in ES cells  
(Suh et al., 2004) 
mmu-miR-292-5p 
-4373324 -13.865 2.39E-05 
Highly expressed in ES cells  
(Zheng et al., 2011) 
mmu-miR-302d 
-4373063 -12.609 1.30E-08 
Highly expressed in ES cells  
(Suh et al., 2004) 
mmu-miR-200a* 
-4373273 -12.465 1.42E-02 
Repress neural induction in 
human ES cells 
(Du et al., 2013) 
mmu-miR-721 
-4381073 -9.216 7.44E-04  
mmu-miR-200b* 
-4395385 -8.978 3.77E-03 
Repress neural induction in 
human ES cells 
(Du et al., 2013) 
mmu-miR-375 
-4373027 -8.810 1.44E-02 
Promote beta pancreatic 
differentiation in human iPS 
cells 
(Lahmy et al., 2014) 
mmu-miR-200a 
-4378069 -8.304 3.01E-05 
Repress neural induction in 
human ES cells 
(Du et al., 2013) 
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mmu-miR-326 
-4373335 -7.233 7.30E-03 
Regulate human dopamine D2 
receptor expression 
(Shi et al., 2014) 
mmu-miR-293 
-4386754 -6.613 2.35E-07 
Highly expressed in ES cells  
(Zheng et al., 2011) 
mmu-miR-290-3p 
-4395721 -5.923 5.78E-07 
Highly expressed in ES cells  
(Zheng et al., 2011) 
 
Follow-up study with ES cells which express a combination of miRNAs upregulated by SMI1 
can be applied in order to see the functional impacts of miRNAs in the directed differentiation to 
skeletal muscle. Cross analysis between decreased mRNA and increased miRNA level or 
increased mRNA and decreased miRNA will be useful to identify networks which are involved 
in the mechanism of SMI1. Further, analyzing the common seed sequences and targets of 
miRNAs affected by SMI can give ideas for further mechanism identification studies of SMI1.  
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3.2 mRNA Microarray during early embryonic skeletal muscle differentiation by SMI1 
 
To identify the direct events of SMI, comprehensive mRNA level analysis was carried out with 
RNAs which were prepared from untreated EBs and EBs incubated with SMI1 and its higher 
efficient analogue SMI2 for 2, 6 and 24 hours. Microarray analysis was carried out with 
Affymetrix Mouse430 2.0 GeneChip. 
 
3.2.1 mRNA levels at 2 hours incubation 
After 2 hours of incubation, there is no change by SMIs (Fig. 3.1A and B) (Criteria to screen the 
probes were fold changes more than 2 and relative expression level more than 50).  
 
3.2.2 mRNA levels at 6 hours incubation 
 
Furthermore, 6 hours incubation did not give dramatic changes in terms of gene expression level. 
Only a few genes were significantly changed with more than 2 fold changes. By SMI1, Bhlha15 
(also known as Mist1) and Krtdap were decreased (Fig. 3.2A). Interestingly alsoBhlha15 and a 
not annotated cDNA were downregulated by SMI2 (Fig. 3.2B). Not any single gene was 
upregulated by each compound by 6 hours incubation with more than 2 fold change. However, 
expression levels of the 3 genes which were downregulated were very low over all the time 
points. Nevertheless it is interesting that two independent compounds showed one identical gene 
expression change, Mist1. Mist1 was reported as a transcriptional repressor of MyoD in 
myoblasts differentiation (Lemercier et al., 1998). Mist1 is also a basic helix-loop-helix protein 
(bHLH) and its expression pattern is overlapped partially with the MyoD protein family in 
proliferating myoblasts. Mist1 forms homodimers and heterodimers with MyoD and E-proteins 
in order to inhibit MyoD activity. Although there is a time gap between embryonic skeletal 
muscle differentiation and myoblasts differentiation, studying the role of Mist1 during 
embryonic skeletal muscle differentiation will be worth. Mist1 appears in skeletal muscle-
forming regions during embryonic days E12.5 and E16.5.  
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(A) 
 
(B) 
 
Figure 3.2: mRNA levels from EBs incubated with SMIs for 2 hours  
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(A) 
 
(B) 
 
Figure 3.3: mRNA levels from EBs incubated with SMIs for 6 hours  
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3.2.3 mRNA levels at 24 hours incubation 
 
After 24 hours incubation, more changes of gene expression were observed compared to 2 and 6 
hours incubation. SMI1 induced more gene expression changes than SMI2.  
From downregulated genes by SMI1 after filtering genes whose expressions are low (intensity 
less than 50), 5 genes were identified, which are Lifr, Lrrc2, Mreg, Mtap7 and TET2 (Fig. 3.3A). 
LIF (Leukemia Inhibitory Factor) is a member of the interleukin-6 family of cytokines. It binds 
to a receptor complex consisting of a LIF specific receptor (LIFR) and the signal transducer 
gp130 (Gearing et al., 1992). In mouse ES cells and adipocytes culture, LIF also acts as an 
inhibitor of differentiation. In embryoid bodies differentiation, LIF modulates cardiogenesis in 
two different ways depending on the stage of differentiation (Bader et al., 2000). At the period 
when mesodermal precursors of cardiomyocyte form in EBs, presence of LIF delayed the 
commitment to cardiomyocyte significantly.  
Furthermore, Eif4g3, Gpb1, Gbp2, Gpm6a, Id2, Psmb8, Sox1, Tspan6 and Zbp1 are the set of 
genes which were upregulated by 24 hours incubation with SMI1. By SMI2, Bcl11a, Bcll11b, 
Dusp9, Enpp2, Etv4, Lrrc2, Mtap7, Tnnt1 and Zfp827 were identified as downregulated genes 
after 24 hours incubation. Only Hoxa3 was upregulated significantly by SMI2 at that time point.  
The signature in common from the two compounds was the downregulation of Lrrc2 and Mtap7. 
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Figure 3.4: mRNA levels from EBs incubated with SMIs for 24 hours  
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Lrrc2 and Mtap7 are in the list of genes which are downregulated by both SMI1 and SMI2 with 
24 hours incubation. Lrrc2 is Leucine Rich Repeat Containing Protein 2. In human LRRC2 
transcript was detected only in heart, skeletal muscle and kidney (Kiss et al., 2002). Its exact 
function is not elucidated yet. Lrrc2 may be related to tumorigenesis because RSP-1 (Ras 
Suppressor Protein 1), the closest relative of Lrrc2 with seven leucine-rich repeats, is capable of 
suppressing v-ras transformation in vitro (Cutler et al., 1992). Mtap7 is a microtubule-associated 
protein and is involved in microtubule dynamics. One identified function of Mtap7 in mouse is 
an essential role in microtubule function for spermatogenesis (Magnan et al., 2009).  
To find out the significance of these two downregulated genes in regard of skeletal muscle 
differentiation, I have applied siRNA (small interfering RNA) approach to modify the level of 
Lrrc2 and Mtap7 during ES cell differentiation. Reverse transfection of siRNAs was carried out 
upon ES cell culture. EBs were made after 48 hours from transfection. It showed reduced Mtap7 
mRNA level to less than 60%. Reduced Mtap7 level by siRNA increased Pax3 at EB day 4+4. 
At EB day 4+8 there is a tendency that Myogenin mRNA level was increased. However, the 
skeletal muscle phenotype was not seen by visual examination under microscope. Stable 
knockdown or knockout could improve this effect of Mtap7 since the duration of siRNA is 
generally short and transient. Also the decreased level of Mtap7 by siRNA could be also 
improved by using stable knockdown. In contrast to Mtap7 siRNA against Lrrc2 showed no 
effect on the level of Pax3 and Myogenin (data not shown). 
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Figure 3.5: mRNA levels measured by real-time RT-PCR. (A) Mtap7 mRNA in ES 
cells after 48 hours from siRNA transfection. (B) Pax3 mRNA level at EB day 4+4. 
Error bars indicate the standard deviation of 3 samples of 10 individual EBs. (C) 
Myogenin mRNA level at EB day4+10. Error bars indicate the standard deviation of 3 
samples of 10 individual EBs. 
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Chapter 4:  Concluding remarks and future prospects 
 
In this thesis, I have investigated two small molecules (SMA1 and SMA2) driving mouse EBs to 
skeletal muscle. In order to elucidate the mechanism of action of SMAs, we analyzed the level of 
mRNA from EBs in either presence or absence of SMA1. Based on mRNA Microarray data, we 
applied the pathway analysis and gene set enrichment analysis. From our work, we can draw the 
major conclusion that the concerted modulation of Wnt pathway, Smad2/3 signaling and Shh 
pathway is important in skeletal muscle differentiation from mouse ES cells. And I confirmed 
this hypothesis that the modulation of these three pathways by known small molecules was 
sufficient to differentiate skeletal muscle from mouse embryonic stem cells. 
 
The role of Wnt pathway activation in the myogenic program during development has been well 
documented (Rios et al., 2011). Wnt1 and Wnt3 are secreted from the dorsal neural tube and are 
positively involved in somite patterning. During ES cell differentiation, Wnt pathway activation 
is critical for skeletal muscle differentiation (Borchin et al., 2013; Shelton et al., 2014; Xu et al., 
2013), while inhibition of Wnt pathway is necessary for cardiac muscle differentiation (Wang et 
al., 2011).  
 
Smad2/3 signaling activation by Nodal/Activin A is important for endoderm specification during 
development (Schier and Shen, 2000). I speculate that SMI may guide the EB to the mesoderm 
formation by inhibiting endoderm formation which is a very prominent pathway in early EB 
differentiation. The role of Shh in skeletal muscle differentiation is less clear. Previous reports 
explained that Shh regulates skeletal muscle precursor cell survival, proliferation and 
differentiation during vertebrate’s development (Reviewed in Bentzinger et al., 2012). However, 
presence of skeletal muscle in Shh knockout mice suggests that skeletal muscle can be formed 
without Shh (Chiang et al., 1996). It is important to note that our in vitro EB differentiation 
system does not produce the structures resembling somites which appear during embryo 
development in vivo. Therefore the effect of these pathways could act in different ways 
compared to the in vivo situation where a somite is formed. 
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 Future prospects 
 
With the findings about skeletal muscle differentiation from mouse ES cells in this thesis, there 
are still open questions. The future directions described below will improve the mouse 
embryonic stem cells as a discovery tool in skeletal muscle biology. 
 
1. Further characterization of skeletal muscle induced by SMI  
Skeletal muscle derived from mouse ES cells by SMI showed dynamic and dramatic twitching 
movement on the culture plate, starting around 2 weeks of differentiation. However, it was not 
tested if these skeletal muscles could integrate and recover the phenotype of animal models of 
skeletal muscle disease. In the report of Darabi and colleague, the skeletal muscle from mouse 
ES cells could restore the functional properties in mdx disease model mice (Darabi et al., 2008). 
It will be of great interest to test injection of ES cell derived skeletal muscle to see if they can 
ameliorate the pathology in vivo. To inject these cells in mdx mice, a model for Duchenne 
muscluar dystrophy, and look for their integration for the possible improvement of the muscular 
function would be a great chance to show the potential of our cells. Also the presence of 
neuromuscular junction in our culture system is needed to be tested. If there are motor neurons 
innervated to skeletal muscle, the protocol we established can be applied to the research of 
motor-neuron disease area as a cellular model. 
 
2. Protocol transfer to human pluripotent stem cells 
The protocol we established in this thesis was not optimized in human pluripotent stem cells 
differentiation system. The SMI could not generate skeletal muscle from human pluripotent stem 
cells so far (data not shown). Interestingly BSL protocol modifying Wnt, Smad and Shh pathway 
could induces early markers from the preliminary experiments. However, the differentiation 
could not lead to the mature phenotype of skeletal muscle. The reason could be because the 
protocol that we tested was not optimal. In mouse EB differentiation, SMI1 and BSL protocol 
showed different efficiency of skeletal muscle differentiation depending on the time points and 
concentrations of treatment. Testing different protocols combining different time points and 
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concentrations during the differentiation of human ES or iPS cells will give an answer to this 
question. It is important to consider that normally differentiation protocols in human ES or iPS 
cells are more than approximately 3 times slower compared to mouse cells. The culture condition 
for example EB formation, attached culture and serum in the medium could affect the whole 
process of skeletal muscle differentiation. 
Originally SMI1 was identified from a GPCR (G-protein coupled receptor) modulating 
compounds set. The molecules were collected based on the observation of GPCR modulating 
activity from elsewhere. It was confirmed that SMI1 works as a Gi receptor agonist in SW982 
cells. Unfortunately the relevant receptor could not be identified by co-incubation of SMI with 
known GPCR agonist/antagonist. The activity modulation on the specific receptors remains to be 
tested. New strategy can be to knockout a GPCR in SW982 via Crispr gene editing technique to 
identify the functional receptor that inhibits SMI’s action in knockout cell lines (Cho et al., 2013). 
Previously knockout or knockdown approach was difficult due to the low transfection efficiency 
in SW982 cells. By identifying the GPCR which SMI1 interacts with, we will understand the 
direct mechanism of action of SMI. Once the receptor is revealed, the modulation of that 
receptor activity could be also used for a protocol transfer to human pluripotent stem cells. 
 
3. Pull down assay for direct target identification 
One of the first approaches to understand small molecule’s mechanisms is the identification of 
the binding proteins which interact with the molecule. Extensive structure activity relationship 
(SAR) studies of SMI1 guided us to understand essential functional groups in the structure for its 
activity. This knowledge allows us to add a linker to either urea or nitrate group, resulting in 
linker analogues with similar activity to the original SMI1 compound. Protein lysate of EB day 1 
was taken to perform pull-down assay using active SMI linker analogue (Methods described in 
Huang et al., 2009). Unfortunately we could not identify any probable binding target from EB 
lysate (data not shown). Most reliable interpretation of this result is that the target is either 
membrane bound, low abundance or very small size protein. Or, if the interaction between 
analogue and target is weak, it could not be identified by this method either.  
As an alternative tool of labeling and detecting the SMI1 linker molecule, we took advantage of 
click chemistry in cell culture situation (Koo et al., 2012). However the effort for tracing the 
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localization of SMI1 with fluorophore with click chemistry did not work out (data not shown). It 
can be due to the absence of target inside of the cells or the weak binding affinity between SMI1 
and target. Probably without cross linking step, compound could be washed away while cells are 
processed for click chemistry. For the strategy to include the cross linking step before labeling, I 
also found an analogue containing a part that is compatible to photo affinity labeling (PAL) with 
UV crosslinking. It would be of interest to test this analogue if this binds to the components in 
cells with competing manner with the parental compound.   
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Abbreviation List 
 
Alk Activin Receptor-like Kinase 
APC  Adenomatous Polyposis Coli 
BMP  Bone Morphogenic Protein 
DGC Dystrophin Glycoprotein Complex 
DMD Duchenne Muscular Dystrophy  
DMPK Dystrophia Myotonica Protein Kinase  
EB  Embryoid Body 
ESC  Embryonic Stem Cells 
GPCR G-protein coupled receptor 
GSK  Glycogen Synthase Kinase 
Hh  Hedgehog 
IP Immunoprecipitation 
iPS Induced Pluripotent Stem 
LIF Leukemia Inhibitory Factor 
MHC  Myosin Heavy Chain 
MRF  Myogenic regulatory factor 
MyoG  Myogenin 
NFAT Nuclear Factor of Activated T-cells 
PKC Protein Kinase C 
PSM  Presomitic Mesoderm 
RA  Retinoic Acid 
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RAR  Retinoic Acid Receptor 
R-Smad  Receptor-regulated Smad  
SAR  Structure Activity Relationship  
sFRP Secreted Frizzled-related protein 
Shh Sonic Hedgehog 
siRNA Small Interfering RNA  
Smo Smoothened 
SRF Serum Response Factor  
TGF Transforming Growth Factor 
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